Unnamed: 0.1,Unnamed: 0,NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,nct_id,criteria,year,duration_years,similarity_score,rank,enrollment_size,has_results,completion_status,complexity_score,sentiment_score,common_conditions,common_interventions
43799,55680,NCT00408629,Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis,https://clinicaltrials.gov/study/NCT00408629,,COMPLETED,"This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of the human anti-tumor necrosis factor (TNF) monoclonal antibody adalimumab (ADA) in patients with moderately to severely active ulcerative colitis (UC).",YES,Ulcerative Colitis,BIOLOGICAL: adalimumab|BIOLOGICAL: placebo,"Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8, Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:

Stool Frequency Subscore (SFS), Rectal Bleeding Subscore (RBS), Endoscopy Subscore, and Physician's Global Assessment Subscore (PGA), each of which ranges from 0 (normal) to 3 (severe disease)., Week 8|Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52, Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:

SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease)., Week 52","Proportion of Participants Who Achieved Sustained Clinical Remission Per Mayo Score at Both Week 8 and Week 52, Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:

SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease)., Week 8, Week 52|Proportion of Participants Who Achieved Clinical Response Per Mayo Score at Week 8, Clinical response per Mayo score is defined as a decrease in Mayo score of at least 3 points and at least 30% from Baseline, plus either a decrease in rectal bleeding subscore (RBS) of at least 1 point from Baseline or an absolute RBS of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:

SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease)., Week 8|Proportion of Participants Who Achieved Clinical Response Per Mayo Score at Week 52, Clinical response per Mayo score is defined as a decrease in Mayo score of at least 3 points and at least 30% from Baseline, plus either a decrease in RBS of at least 1 point from Baseline or an absolute RBS of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:

SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease)., Week 52|Proportion of Participants Who Achieved Sustained Clinical Response Per Mayo Score at Both Week 8 and Week 52, Clinical response per Mayo score is defined as a decrease in Mayo score of at least 3 points and at least 30% from Baseline, plus either a decrease in RBS of at least 1 point from Baseline or an absolute RBS of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:

SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease)., Week 8, Week 52|Proportion of Participants Who Achieved Mucosal Healing at Week 8, Mucosal healing is defined as an Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows:

0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease(spontaneous bleeding, ulceration)., Week 8|Proportion of Participants Who Achieved Mucosal Healing at Week 52, Mucosal healing is defined as an Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows:

0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease(spontaneous bleeding, ulceration)., Week 52|Proportion of Participants Who Achieved Sustained Mucosal Healing at Both Week 8 and Week 52, Mucosal healing is defined as an Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows:

0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease(spontaneous bleeding, ulceration)., Week 8, Week 52|Proportion of Participants Who Discontinued Corticosteroid Use Before Week 52 and Achieved Clinical Remission Per Mayo Score at Week 52, Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:

SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease)., Baseline to Week 52|Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 8, The PGA includes the 3 other subscores (SFS, RBS, and Endoscopy), the participant's daily record of abdominal discomfort and functional assessment, and other observations such as physical findings and the participant's performance status. Possible scores range from 0-3 as follows:

0 = Normal (other subscores are 0), 1 = Mild disease (other subscores are mostly 1), 2 = Moderate disease (other subscores are 1 to 2), 3 = Severe disease (other subscores are 2 to 3)., Week 8|Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 8, SFS ranges from 0-3 as follows:

0 = Normal number of stools for this participant, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal. The participant served as his/her own control., Week 8|Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (a Score of 0 or 1) at Week 8, RBS ranges from 0-3 as follows:

0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, 3 = blood alone passed, Week 8|Proportion of Participants Who Discontinued Corticosteroid Use for At Least 90 Days and Achieved Clinical Remission Per Mayo Score at Week 52, Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:

SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease)., Baseline to Week 52|Proportion of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission Per Mayo Score (Sustained) at Both Weeks 32 and 52, Clinical remission per Mayo score is defined as a total Mayo score of at least 2 and no individual subscore greater than 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores:

SFS, RBS, Endoscopy Subscore, and PGA, each of which ranges from 0 (normal) to 3 (severe disease)., Week 32, Week 52|Proportion of Inflammatory Bowel Disease Questionnaire Responders at Week 52, Response per the Inflammatory Bowel Disease Questionnaire (IBDQ) was defined as at least a 16-point increase from Baseline in total IBDQ score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to questions within each domain range from 1 (significant impairment) to 7 (no impairment), with total score ranging from 32 (very poor) to 224 (perfect health-related quality of life)., Week 52|Proportion of Inflammatory Bowel Disease Questionnaire Responders at Week 8, Response per the Inflammatory Bowel Disease Questionnaire (IBDQ) was defined as at least a 16-point increase from Baseline in total IBDQ score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to questions within each domain range from 1 (significant impairment) to 7 (no impairment), with total score ranging from 32 (very poor) to 224 (perfect health-related quality of life)., Week 8",,Abbott,,ALL,"ADULT, OLDER_ADULT",PHASE3,518.0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",M06-827|2006-002782-40,2006-11,2010-03,2010-03,2006-12-07,2011-03-31,2011-05-03,"Site Ref # / Investigator 5394, Anaheim, California, 92801, United States|Site Ref # / Investigator 3753, Wheat Ridge, Colorado, 80033, United States|Site Ref # / Investigator 3754, Hamden, Connecticut, 06518, United States|Site Ref # / Investigator 12903, Gainesville, Florida, 32607, United States|Site Ref # / Investigator 3747, Hollywood, Florida, 33021, United States|Site Ref # / Investigator 5106, Jacksonville, Florida, 32256, United States|Site Ref # / Investigator 11601, Naples, Florida, 34102, United States|Site Ref # / Investigator 6846, Sarasota, Florida, 34239, United States|Site Ref # / Investigator 3742, Winter Park, Florida, 32789, United States|Site Ref # / Investigator 3760, Zephyrhills, Florida, 33542, United States|Site Ref # / Investigator 3739, Atlanta, Georgia, 30342, United States|Site Ref # / Investigator 7658, Macon, Georgia, 31201, United States|Site Ref # / Investigator 5397, Moline, Illinois, 61265, United States|Site Ref # / Investigator 7453, Topeka, Kansas, 66606, United States|Site Ref # / Investigator 3759, Annapolis, Maryland, 21401, United States|Site Ref # / Investigator 3762, Annapolis, Maryland, 21401, United States|Site Ref # / Investigator 3738, Lutherville, Maryland, 21093, United States|Site Ref # / Investigator 7472, Troy, Michigan, 48098, United States|Site Ref # / Investigator 3744, Rochester, Minnesota, 55905, United States|Site Ref # / Investigator 6088, St. Louis, Missouri, 63128, United States|Site Ref # / Investigator 3756, Great Neck, New York, 11021, United States|Site Ref # / Investigator 3752, Charlotte, North Carolina, 28207, United States|Site Ref # / Investigator 3758, Jacksonville, North Carolina, 28546, United States|Site Ref # / Investigator 3745, Cincinnati, Ohio, 45219, United States|Site Ref # / Investigator 7709, Oklahoma City, Oklahoma, 73104, United States|Site Ref # / Investigator 3740, Tulsa, Oklahoma, 74104, United States|Site Ref # / Investigator 3765, Sayre, Pennsylvania, 18840, United States|Site Ref # / Investigator 3741, Columbia, South Carolina, 29204, United States|Site Ref # / Investigator 3737, Germantown, Tennessee, 38138, United States|Site Ref # / Investigator 6077, Nashville, Tennessee, 37203, United States|Site Ref # / Investigator 5107, Nashville, Tennessee, 37205, United States|Site Ref # / Investigator 3743, Nashville, Tennessee, 37212-1610, United States|Site Ref # / Investigator 5398, Ogden, Utah, 84405, United States|Site Ref # / Investigator 8064, Spokane, Washington, 99202, United States|Site Ref # / Investigator 3750, Spokane, Washington, 99204, United States|Site Ref # / Investigator 3761, West Bend, Wisconsin, 53095, United States|Site Ref # / Investigator 6853, Buenos Aires, C1181ACH, Argentina|Site Ref # / Investigator 13722, Garran, Australian Capital Territory, 2605, Australia|Site Ref # / Investigator 16141, Bankstown, New South Wales, NSW 2200, Australia|Site Ref # / Investigator 13723, Herston, Queensland, 4029, Australia|Site Ref # / Investigator 10706, Bedford Park, South Australia, SA 5042, Australia|Site Ref # / Investigator 14882, Box Hill, Victoria, 3128, Australia|Site Ref # / Investigator 9002, Malvern, Victoria, 3144, Australia|Site Ref # / Investigator 10704, Fremantle, Western Australia, 6160, Australia|Site Ref # / Investigator 9802, Vienna, 1090, Austria|Site Ref # / Investigator 5256, Bonheiden, 2820, Belgium|Site Ref # / Investigator 5253, Brussels, 1070, Belgium|Site Ref # / Investigator 6225, Brussels, 1200, Belgium|Site Ref # / Investigator 6079, Ghent, 9000, Belgium|Site Ref # / Investigator 6078, Leuven, 3000, Belgium|Site Ref # / Investigator 10423, Kelowna, British Columbia, B1Y 1Z9, Canada|Site Ref # / Investigator 3766, Victoria, British Columbia, V8T 5G4, Canada|Site Ref # / Investigator 3769, Hamilton, Ontario, L8N 3Z5, Canada|Site Ref # / Investigator 13556, Sudbury, Ontario, P3E 2N8, Canada|Site Ref # / Investigator 3736, Toronto, Ontario, M5G 1X5, Canada|Site Ref # / Investigator 3771, Montreal, Quebec, H3A 1A1, Canada|Site Ref # / Investigator 3764, Montreal, Quebec, H3G 1A4, Canada|Site Ref # / Investigator 3768, Montreal, Quebec, H3T 1E2, Canada|Site Ref # / Investigator 3770, Quebec City, Quebec, G1S 4L8, Canada|Site Ref # / Investigator 7021, Ceske Budejovice, 370 87, Czech Republic|Site Ref # / Investigator 6307, Hradec Kravlove 12, 500 12, Czech Republic|Site Ref # / Investigator 6606, Olomouc, 775 20, Czech Republic|Site Ref # / Investigator 7481, Prague 4, 140 21, Czech Republic|Site Ref # / Investigator 7479, Prague 5, 15006, Czech Republic|Site Ref # / Investigator 6483, Hvidovre, DK-2650, Denmark|Site Ref # / Investigator 7477, Odense C, 5000, Denmark|Site Ref # / Investigator 6231, Clichy, 92110, France|Site Ref # / Investigator 7476, Lille Cedex, 59037, France|Site Ref # / Investigator 7475, Pessac Cedex, 33600, France|Site Ref # / Investigator 7474, Toulouse, 31059, France|Site Ref # / Investigator 15321, Hamburg, 20148, Germany|Site Ref # / Investigator 9069, Hamburg, 22559, Germany|Site Ref # / Investigator 14642, Magdeburg, 39120, Germany|Site Ref # / Investigator 9067, Minden, 32423, Germany|Site Ref # / Investigator 14761, Muenster, 48159, Germany|Site Ref # / Investigator 14661, Munich, 80639, Germany|Site Ref # / Investigator 9801, Munich, 81377, Germany|Site Ref # / Investigator 5247, Regensburg, 93053, Germany|Site Ref # / Investigator 7485, Budapest, H-1076, Hungary|Site Ref # / Investigator 5025, Budapest, H-1135, Hungary|Site Ref # / Investigator 10625, Debrecen, 4032, Hungary|Site Ref # / Investigator 14104, Gyula, 5700, Hungary|Site Ref # / Investigator 4987, Miskoic, H-3051, Hungary|Site Ref # / Investigator 5036, Miskolc, H-3526, Hungary|Site Ref # / Investigator 12744, Kfar Saba, 44281, Israel|Site Ref # / Investigator 10623, Petah Tikva, 49100, Israel|Site Ref # / Investigator 15361, Tel Aviv, 64239, Israel|Site Ref # / Investigator 13301, Auckland, 0620, New Zealand|Site Ref # / Investigator 13181, Auckland, 1148, New Zealand|Site Ref # / Investigator 13148, Christchurch, 8011, New Zealand|Site Ref # / Investigator 13482, Hamilton, New Zealand|Site Ref # / Investigator 9561, Gjovik, 2819, Norway|Site Ref # / Investigator 5197, Oslo, 0027, Norway|Site Ref # / Investigator 6297, Oslo, 0514, Norway|Site Ref # / Investigator 5194, Tromso, 9038, Norway|Site Ref # / Investigator 5193, Trondheim, 7006, Norway|Site Ref # / Investigator 5242, Lodz, 90-153, Poland|Site Ref # / Investigator 5266, Warsaw, 02 781, Poland|Site Ref # / Investigator 5265, Warsaw, 02-507, Poland|Site Ref # / Investigator 15263, Wroclaw, 54-144, Poland|Site Ref # / Investigator 5264, Faro, 8000-386, Portugal|Site Ref # / Investigator 7473, Lisbon, 1150-314, Portugal|Site Ref # / Investigator 5263, Lisbon, 1769-001, Portugal|Site Ref # / Investigator 5211, Barcelona, 08036, Spain|Site Ref # / Investigator 5212, Madrid, 28040, Spain|Site Ref # / Investigator 10221, Basel, 4031, Switzerland|Site Ref # / Investigator 10222, Bern, 3010, Switzerland|Site Ref # / Investigator 9162, Zurich, 8091, Switzerland",,NCT00408629,"Inclusion Criteria:~1. Participants \>=18 years of age and in good health (Investigator discretion) with a recent stable medical history~2. Diagnosis of UC for greater than 90 days prior to Baseline~3. Diagnosis of active UC confirmed by colonoscopy with biopsy or flexible sigmoidoscopy with biopsy during the Screening Period, with exclusion of infection~4. Active UC with a Mayo score of 6 to 12 points and endoscopy subscore of 2 to 3 points, despite concurrent treatment with at least 1 of the following (oral corticosteroids or immunosuppressants or both as defined below):~   * Stable oral corticosteroid dose (prednisone \>= 20 mg/day or equivalent) for at least 14 days prior to Baseline or maintenance, corticosteroid dose (prednisone \< 20 mg/day or equivalent) for at least 40 days prior to Baseline~   and/or~  * At least a 90 day course of azathioprine (AZA) or 6-mercaptopurine (6-MP) prior to Baseline, with a dose of AZA \>= 1.5 mg/kg/day or 6-MP \>= 1 mg/kg/day (rounded to the nearest available tablet formulation), or a dose that is the highest tolerated by the participant (e.g., due to leukopenia, elevated liver enzymes, nausea) during that time. Participant must be on a stable dose for at least 28 days prior to Baseline.~   Concurrent therapy was not required for participants who were previously treated with corticosteroids or immunosuppressants (AZA or 6-MP) during the past 5 years and in the judgment of the Investigator have failed to respond to, or could not tolerate, their treatment.~5. Participants may have been included if they had previously used an anti-tumor necrosis factor (TNF) agent (except ADA) and discontinued its use due to a loss of response or intolerance to the agent.~6. Had to be able to self-administer or had caregiver who could reliably administer subcutaneous (SC) injections.~7. Had to be able and willing to give written informed consent and to comply with the requirements of the study protocol.~8. Female had to be either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or of childbearing potential and practicing an approved method of birth control throughout the study and for 150 days after the last dose of study drug. Examples of approved methods of birth control included the following:~   * Condoms, sponge, foams, jellies, diaphragm, or intrauterine device~  * Oral, parenteral, intravaginal contraceptives for 90 days prior to study drug administration~  * A vasectomized partner The results of the serum pregnancy test performed at the Screening Visit and urine pregnancy test performed at the Baseline Visit must have been negative.~9. Judged to be in generally good health as determined by the Investigator~Exclusion Criteria:~1. History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for UC, or planned bowel surgery.~2. Received previous treatment with ADA or previous participation in an ADA clinical study.~3. Received cyclosporine, tacrolimus, or mycophenolate mofetil within 30 days of Baseline.~4. Received intravenous (IV) corticosteroids within 14 days of Screening or during the Screening Period.~5. Received therapeutic enema or suppository, other than required for endoscopy, within 14 days of the Screening endoscopy and during the remainder of the Screening Period.~6. Current diagnosis of fulminant colitis and/or toxic megacolon.~7. Disease limited to the rectum (ulcerative proctitis).~8. Current diagnosis of indeterminate colitis.~9. Current diagnosis and/or history of Crohns disease (CD).~10. Currently receiving total parenteral nutrition.~11. Used aminosalicylates for \< 90 days before Baseline or not on a stable dose for at least 28 days before Baseline or discontinued use within 28 days of Baseline.~12. Positive Clostridium difficile stool assay.~13. Previously used infliximab or any anti-TNF agent within 56 days of Baseline.~14. Previously used infliximab or any anti-TNF agent without clinical response at any time (primary non-responder) unless subject experienced a treatment-limiting reaction.~15. Infections requiring treatment with IV antibiotics, antivirals, or antifungals within 30 days of Baseline or oral antibiotics, antivirals, or antifungals within 14 days of Baseline.~16. History of malignancy other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix. If the Screening colonoscopy/flexible sigmoidoscopy showed evidence of dysplasia or a malignancy, subject was not to be enrolled in the study.~17. History of listeria, histoplasmosis, chronic or active hepatitis B infection, human immunodeficiency virus (HIV), immunodeficiency syndrome, central nervous system demyelinating disease, or untreated tuberculosis (TB).~18. Female subject who was pregnant or breast-feeding or considering becoming pregnant during the study (there should be at least 150 days between the last dose of study drug and either conception or initiation of breast-feeding in women of childbearing potential).~19. Poorly controlled medical condition(s), such as uncontrolled diabetes, unstable ischemic heart disease, moderate to severe congestive heart failure (CHF), recent cerebrovascular accident, and any other condition, which in the opinion of the investigator, put the subject at risk by participation in the protocol.~20. Received any investigational agent within 30 days or 5 half lives prior to Baseline (whichever was longer).~21. History of clinically significant drug or alcohol abuse during the past year.~22. Known hypersensitivity to the excipients of ADA as stated in the label.~23. Any prior exposure to Tysabri® (natalizumab), or Orencia® (abatacept) or any other biological therapy \[other than Kineret® (anakinra) and anti-TNF agents\].~24. Currently taking both budesonide and prednisone (or equivalent) simultaneously.",,,0.9986675,1,518.0,1.0,COMPLETED,2.83,-0.044,1,0
72918,92692,NCT00853099,A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis,https://clinicaltrials.gov/study/NCT00853099,,COMPLETED,The purpose of this study is to assess the efficacy and safety of adalimumab in Japanese subjects with moderately to severely active ulcerative colitis (UC).,YES,Ulcerative Colitis,BIOLOGICAL: adalimumab|DRUG: placebo,"Percentage of Participants With Clinical Remission at 8 Weeks, Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore \> 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores:

* Stool Frequency Subscore (SFS), based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal);
* Rectal Bleeding Subscore (RBS), based on the participant's diary and scored from zero (no blood) to three (blood only passed);
* Endoscopy Subscore (ESS), based on colonoscopy or sigmoidoscopy and scored from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration);
* Physician's Global Assessment (PGA) subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease).

The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease., Week 8|Percentage of Participants With Clinical Remission at 52 Weeks, Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore \> 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores:

* Stool Frequency Subscore (SFS), based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal);
* Rectal Bleeding Subscore (RBS), based on the participant's diary and scored from zero (no blood) to three (blood only passed);
* Endoscopy Subscore (ESS), based on colonoscopy or sigmoidoscopy and scored from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration);
* Physician's Global Assessment (PGA) subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease).

The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease., Week 52","Percentage of Participants With Clinical Remission at 8, 32, and 52 Weeks, Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore \> 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores:

* Stool Frequency Subscore (SFS), based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal);
* Rectal Bleeding Subscore (RBS), based on the participant's diary and scored from zero (no blood) to three (blood only passed);
* Endoscopy Subscore (ESS), based on colonoscopy or sigmoidoscopy and scores from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration);
* Physician's Global Assessment (PGA) subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease).

The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease., Weeks 8, 32, and 52|Percentage of Participants With a Clinical Response, A clinical response was defined as a decrease in Mayo score of ≥ 3 points and ≥ 30% from Baseline PLUS a decrease in the Rectal Bleeding Subscore (RBS) ≥ 1 or an absolute RBS of 0 or 1.

The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores:

* Stool Frequency Subscore, based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal);
* Rectal Bleeding Subscore, based on the participant's diary and scored from zero (no blood) to three (blood only passed);
* Endoscopy Subscore, based on colonoscopy or sigmoidoscopy and scored from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration);
* Physician's Global Assessment subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease).

The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease., Baseline and Weeks 8, 32, and 52|Percentage of Participants With Mucosal Healing, Mucosal healing was defined as an endoscopy subscore of ≤ 1 and was assessed using flexible sigmoidoscopy performed at Weeks 8, 32, and 52.

The endoscopy subscore ranges from zero to three as follows:

0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration)., Weeks 8, 32, and 52|Percentage of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (≤ 1), Rectal bleeding was assessed from the participant's diary, taking the worst score from the 3 days prior to each study visit. The rectal bleeding subscore ranges from zero to three, according to the following scale:

0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, 3 = blood alone passed., Weeks 8, 32, and 52|Percentage of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (≤ 1), The Physician's Global Assessment Subscore acknowledges the three other subscores (Stool Frequency, Rectal Bleeding, and Endoscopy), the participant's daily record of abdominal discomfort and functional assessment, and other observations such as physical findings and the participant's performance status. Possible scores range from zero to three as follows:

0 = Normal (other subscores are 0), 1 = Mild disease (other subscores are mostly 1), 2 = Moderate disease (other subscores are 1 to 2), 3 = Severe disease (other subscores are 2 to 3)., Weeks 8, 32, and 52|Percentage of Participants With Stool Frequency Subscore Indicative of Mild Disease (≤ 1), Stool frequency was assessed from the participant's diary, taking the worst score from the 3 days prior to each study visit. The stool frequency subscore ranges from zero to three, according to the following scale:

0 = Normal number of stools for this participant, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal., Weeks 8, 32, and 52|Percentage of Inflammatory Bowel Disease Questionnaire (IBDQ) Responders, An inflammatory bowel disease questionnaire responder was defined as a participant with at least a 16-point increase from Baseline in total Inflammatory Bowel Disease Questionnaire (IBDQ) score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to each question within each domain range from 1 (significant impairment) to 7 (no impairment), with the total score ranging from 32 (very poor) to 224 (perfect health-related quality of life)., Baseline and Weeks 8, 32, and 52|Number of Participants With Adverse Events up to Week 8, An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.

A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.

For more details on adverse events please see the Adverse Event section below., 8 weeks|Number of Participants With Adverse Events up to Week 52, An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.

A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.

For more details on adverse events please see the Adverse Event section below., 52 weeks|Number of Participants With Adverse Events During the Adalimumab Treatment Period, An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.

A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.

For more details on adverse events please see the Adverse Event section below., 221 weeks",,"AbbVie (prior sponsor, Abbott)","Eisai Co., Ltd.",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,274.0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",M10-447,2009-02,2011-05,2013-08,2009-03-02,2012-11-27,2014-09-05,"Site Reference ID/Investigator# 47136, Asahikawa, Japan|Site Reference ID/Investigator# 47159, Chiba, Japan|Site Reference ID/Investigator# 47183, Chikushino, Japan|Site Reference ID/Investigator# 47135, Fukuoka-shi, Japan|Site Reference ID/Investigator# 47182, Fukuoka-shi, Japan|Site Reference ID/Investigator# 47124, Hamamatsu, Japan|Site Reference ID/Investigator# 47130, Hirakata-shi, Japan|Site Reference ID/Investigator# 47103, Hirosaki, Japan|Site Reference ID/Investigator# 47131, Hiroshima-shi, Japan|Site Reference ID/Investigator# 47178, Hiroshima, Japan|Site Reference ID/Investigator# 47179, Hiroshima, Japan|Site Reference ID/Investigator# 47176, Izumo, Japan|Site Reference ID/Investigator# 47226, Kagoshima, Japan|Site Reference ID/Investigator# 47123, Kanazawa-shi, Japan|Site Reference ID/Investigator# 47160, Kashiwa, Japan|Site Reference ID/Investigator# 47108, Kawagoe, Japan|Site Reference ID/Investigator# 47107, Koshigaya, Japan|Site Reference ID/Investigator# 47181, Kurume, Japan|Site Reference ID/Investigator# 47222, Kurume, Japan|Site Reference ID/Investigator# 47223, Kurume, Japan|Site Reference ID/Investigator# 47170, Kyoto-shi, Japan|Site Reference ID/Investigator# 47171, Kyoto-shi, Japan|Site Reference ID/Investigator# 47127, Kyoto, Japan|Site Reference ID/Investigator# 47172, Kyoto, Japan|Site Reference ID/Investigator# 47134, Matsuyama-shi, Japan|Site Reference ID/Investigator# 47225, Miyazaki, Japan|Site Reference ID/Investigator# 47138, Morioka-shi, Japan|Site Reference ID/Investigator# 47168, Nagakute-shi, Japan|Site Reference ID/Investigator# 47125, Nagoya-shi, Japan|Site Reference ID/Investigator# 47126, Nagoya-shi, Japan|Site Reference ID/Investigator# 47166, Nagoya-shi, Japan|Site Reference ID/Investigator# 47122, Niigata-shi, Japan|Site Reference ID/Investigator# 47227, Nishihara, Japan|Site Reference ID/Investigator# 47174, Nishinomiya-shi, Japan|Site Reference ID/Investigator# 47224, Oita, Japan|Site Reference ID/Investigator# 47177, Okayama-shi, Japan|Site Reference ID/Investigator# 47228, Okinawa, Japan|Site Reference ID/Investigator# 47128, Osaka-shi, Japan|Site Reference ID/Investigator# 47129, Osaka, Japan|Site Reference ID/Investigator# 47169, Otsu-shi, Japan|Site Reference ID/Investigator# 47118, Sagamihara-shi, Japan|Site Reference ID/Investigator# 47158, Saitama-shi, Japan|Site Reference ID/Investigator# 47109, Sakura, Japan|Site Reference ID/Investigator# 15853, Sapporo-shi, Japan|Site Reference ID/Investigator# 47137, Sapporo, Japan|Site Reference ID/Investigator# 47104, Sendai-shi, Japan|Site Reference ID/Investigator# 47147, Sendai-shi, Japan|Site Reference ID/Investigator# 47180, Susaki-shi, Japan|Site Reference ID/Investigator# 47133, Takamatsu, Japan|Site Reference ID/Investigator# 47173, Takatsuki-shi, Japan|Site Reference ID/Investigator# 47106, Tokorozawa-shi, Japan|Site Reference ID/Investigator# 47132, Tokushima, Japan|Site Reference ID/Investigator# 47110, Tokyo, Japan|Site Reference ID/Investigator# 47111, Tokyo, Japan|Site Reference ID/Investigator# 47112, Tokyo, Japan|Site Reference ID/Investigator# 47116, Tokyo, Japan|Site Reference ID/Investigator# 47117, Tokyo, Japan|Site Reference ID/Investigator# 47161, Tokyo, Japan|Site Reference ID/Investigator# 47164, Tokyo, Japan|Site Reference ID/Investigator# 47165, Toyama, Japan|Site Reference ID/Investigator# 47167, Toyoake, Japan|Site Reference ID/Investigator# 47105, Yamagata-shi, Japan|Site Reference ID/Investigator# 47175, Yamatotakada, Japan|Site Reference ID/Investigator# 47121, Yokohama-shi, Japan|Site Reference ID/Investigator# 47120, Yokohama, Japan",,NCT00853099,"Inclusion Criteria:~* Diagnosis of ulcerative colitis for greater than 90 days prior to Baseline.~* Active ulcerative colitis with a Mayo Score of 6-12 points at Baseline and endoscopy subscore of 2-3 during the Screening Period, despite concurrent treatment with at least one of the following (oral corticosteroids or immunosuppressants or both as defined below):~* Stable oral corticosteroid dose (prednisolone dose of ≥ 20 mg/day or equivalent) for at least 14 days prior to Baseline or stable oral corticosteroid dose (prednisolone of 5 to less than 20 mg/day) for at least 40 days prior to Baseline. And/or~* At least a consecutive 90-day course of azathioprine or 6-mercaptopurine (6-MP) prior to Baseline, with a dose of azathioprine ≥ 50 mg/day or 6-MP ≥ 30 mg/day, or a dose that was the highest tolerated by the patient.~Exclusion Criteria:~* History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for ulcerative colitis or was planning bowel surgery.~* Patients with disease limited to the rectum.~* Indeterminate colitis and/or Crohn's disease.~* Received any biological therapy (including infliximab) in the past.~* History of tuberculosis or malignancy.~* Pregnant women.~* Patients with positive C. difficile stool assay at Screening.~* Current diagnosis of fulminant colitis and/or toxic megacolon.",,,0.9960624,2,274.0,1.0,COMPLETED,1.57,-0.044,1,0
94460,120130,NCT01647516,Efficacy and Safety Study of Ozanimod in Ulcerative Colitis,https://clinicaltrials.gov/study/NCT01647516,Touchstone,COMPLETED,The purpose of this study is to determine whether RPC1063 is effective in the treatment of ulcerative colitis (UC).,YES,Ulcerative Colitis,DRUG: Ozanimod|DRUG: Placebo,"Percentage of Participants Who Achieved Clinical Remission Based on the Central Read of the Mayo Score (MS), at Week 8, Clinical Remission was defined as: Mayo score of \<2 points and with no individual subscore of \> 1 point.

The Mayo Score is a composite index of four items (stool frequency, rectal bleeding, rectosigmoidoscopy findings, and physician's global assessment) with each item graded semi-quantitatively on a scale of 0 to 3 where 0 represents normal and higher score represents more severe disease status. The total Mayo Score is the sum of the four item scores, with a result ranging from 0 to 12 points. Higher scores represent more severe disease.

* Stool Frequency Subscore (SFS)
* Rectal bleeding Subscore (RBS)
* Endoscopy Subscore
* Physician's Global Assessment (PGA)

Clinical Remission was based on the 4-component Mayo definition., Week 8","Percentage of Participants Who Achieved a Clinical Response in the Mayo Score (MS) at Week 8, Clinical response was defined as a reduction from baseline in Mayo score ≥3 points and ≥30%, and a decrease from baseline in the rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of ≤ 1 point.

The Mayo Score is a composite index of four items (stool frequency, rectal bleeding, rectosigmoidoscopy findings, and physician's global assessment) with each item graded semi-quantitatively on a scale of 0 to 3 where 0 represents normal and higher score represents more severe disease status. The total Mayo Score is the sum of the four item scores, with a result ranging from 0 to 12 points. Higher scores represent more severe disease.

Clinical Respone was based on the 4-component Mayo definition., Week 8|Change From Baseline in Mayo Score at Week 8, The Mayo Score is a composite index of four items (stool frequency, rectal bleeding, rectosigmoidoscopy findings, and physician's global assessment) with each item graded semi-quantitatively on a scale of 0 to 3 where 0 represents normal and higher score represents more severe disease status. The total Mayo Score is the sum of the four item scores, with a result ranging from 0 to 12 points. Higher scores represent more severe disease.

* Stool Frequency Subscore (SFS)
* Rectal bleeding Subscore (RBS)
* Endoscopy Subscore
* Physician's Global Assessment (PGA), Baseline to Week 8|Percentage of Participants With Mucosal Healing at Week 8, Mucosal healing is defined as an endoscopy subscore ≤ 1 point. Endoscopy subscores were calculated based on central endoscopy reading.

The endoscopy scale:

0 = Normal or inactive disease

1. = Mild disease (erythema, decreased vascular pattern, mild friability)
2. = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions)
3. = Severe disease (spontaneous bleeding, ulceration), Week 8|Percentage of Participants Who Achieved Clinical Remission in the Mayo Score at Week 32, Clinical Remission was defined as: Mayo score of \<2 points and with no individual subscore of \> 1 point.

The Mayo Score is a composite index of four items (stool frequency, rectal bleeding, rectosigmoidoscopy findings, and physician's global assessment) with each item graded semi-quantitatively on a score of 0 to 3 where 0 represents normal and higher score represents more severe disease status. The total Mayo Score is the sum of the four item scores, with a result ranging from 0 to 12 points. Higher scores represent more severe disease.

* Stool Frequency Subscore (SFS)
* Rectal bleeding Subscore (RBS)
* Endoscopy Subscore
* Physician's Global Assessment (PGA), Week 32|Percentage of Participants Who Achieved Clinical Response at Week 32, Clinical response was defined as a reduction from baseline in Mayo score ≥3 points and ≥30%, and a decrease from baseline in the rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of ≤ 1 point.

The Mayo Score is a composite index of four items (stool frequency, rectal bleeding, rectosigmoidoscopy findings, and physician's global assessment) with each item graded semi-quantitatively on a scale of 0 to 3 where 0 represents normal and higher score represents more severe disease status. The total Mayo Score is the sum of the four item scores, with a result ranging from 0 to 12 points. Higher scores represent more severe disease.

* Stool Frequency Subscore (SFS)
* Rectal bleeding Subscore (RBS)
* Endoscopy Subscore
* Physician's Global Assessment (PGA), Week 32|Percentage of Participants With Mucosal Healing at Week 32, Mucosal healing is defined as an endoscopy subscore ≤ 1 point. Endoscopy subscores were calculated based on central endoscopy reading.

The endoscopy scale:

0 = Normal or inactive disease

1. = Mild disease (erythema, decreased vascular pattern, mild friability)
2. = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions)
3. = Severe disease (spontaneous bleeding, ulceration), Week 32|Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Induction Period, A TEAE was defined as any event with an onset date on or after first dose date or any ongoing event on the first dose date that worsens in severity after first dose date and until 90 days following the last dose of treatment with the study drug. earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = an AE usually transient in nature and generally not interfering with normal activities; Moderate = an AE that is sufficiently discomforting to interfere with normal activities; Severe = an AE that is incapacitating and prevents normal activities., From the first dose of investigational product (IP) up to 90 days after the last dose of IP or at follow-up visit; the mean total duration of IP exposure was 52.8 days, 56.1 days and 50.8 days respectively for 0.5 mg, 1 mg ozanimod and placebo|Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Maintenance Period, A TEAE was defined as any event with an onset date on or after first dose date or any ongoing event on the first dose date that worsens in severity after first dose date and until 90 days following the last dose of treatment with the study drug. earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = an AE usually transient in nature and generally not interfering with normal activities; Moderate = an AE that is sufficiently discomforting to interfere with normal activities; Severe = an AE that is incapacitating and prevents normal activities., From the first dose of IP up to 90 days after the last dose of IP or at follow-up visit; the mean total duration of IP exposure was 156.3 days, 171.1 days and 154.5 days respectively for 0.5 mg, 1 mg ozanimod and placebo.|Number of Participants With TEAE During the Open-Label Treatment Period (OLP), A TEAE was defined as any event with an onset date on or after first dose date or any ongoing event on the first dose date that worsens in severity after first dose date and until 90 days following the last dose of treatment with the study drug. earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = an AE usually transient in nature and generally not interfering with normal activities; Moderate = an AE that is sufficiently discomforting to interfere with normal activities; Severe = an AE that is incapacitating and prevents normal activities., From the first dose of IP until 90 days after the last dose of IP or at follow-up visit; the mean total duration of study drug exposure in the OLP was 2.42 years",,Celgene,,ALL,"ADULT, OLDER_ADULT",PHASE2,199.0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",RPC01-202,2012-12-26,2015-03-10,2019-08-30,2012-07-23,2020-10-14,2021-05-19,"Anaheim Clinical Trials, Anaheim, California, 92801, United States|University of California San Diego, La Jolla, California, 92037, United States|Alliance Clinical Research, Oceanside, California, 92056, United States|Atlanta Gastroenterology Associates, LLC, Atlanta, Georgia, 30342, United States|Chevy Chase Clinical Research, Chevy Chase, Maryland, 20815, United States|Endoscopic Microsurgery Associates, Towson, Maryland, 21204, United States|Clinical Research Institute of Michigan, LLC, Chesterfield, Michigan, 48047, United States|Long Island Clinical Research Associates, Great Neck, New York, 11021, United States|University of North Carolina, Chapel Hill, North Carolina, 27599, United States|Consultants for Clinical Research, Cincinnati, Ohio, 45219, United States|The Alfred Hospital, Melbourne, Victoria, 3004, Australia|Universitair Ziekenhuis Leuven, Campus Gasthuisberg, Leuven, 3000, Belgium|Multiprofile Hospital for Active Treatment Kaspela, Plovdiv, 4000, Bulgaria|University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic Sofia, Sofia, 1407, Bulgaria|UMHAT Sv Ivan Rilski EAD, Sofia, 1431, Bulgaria|University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD, Sofia, 1527, Bulgaria|Military Medical Academy, Sofia, 1606, Bulgaria|Multiprofile Hospital for Active Treatment Doverie AD, Sofia, 1632, Bulgaria|Multiprofile Hospital for Active Treatment Sveti Panteleimon - Sofia AD, Sofia, 1712, Bulgaria|Multiprofile Hospital for Active Treatment Sofiamed, Sofia, 1797, Bulgaria|Multiprofile Hospital for Active Treatment Sveta Marina EAD, Varna, 9010, Bulgaria|London Health Sciences Centre, University Hospital, London, Ontario, N6A 5A5, Canada|Evaggelismos General Hospital, Athens, 106 76, Greece|University Hospital of Ioannina, Ioannina, 45110, Greece|University Hospital of Larissa, Larissa, 41110, Greece|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, 1062, Hungary|Pannonia Maganorvosi Centrum, Budapest, 1136, Hungary|Uzsoki Utcai Korhaz, Budapest, 1145, Hungary|Vasútegészségügyi Nonprofit Kiemelten Közhasznú Kft. Debreceni Egészségügyi Központja, Debrecen, 4025, Hungary|Barzilai Medical Center, Ashkelon, 7830604, Israel|Carmel Medical Center, Haifa, 34362, Israel|Wolfson Medical Center, Holon, 5822012, Israel|Shaare Zedek Medical Center, Jerusalem, 91031, Israel|Hadassah University Hospital, Jerusalem, 9112001, Israel|Meir Medical Center, Kfar Saba, 44281, Israel|Yeungnam University Medical Center, Daegu, 705717, Korea, Republic of|Konyang University Hospital, Daejon, 302718, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Kangbuk Samsung Medical Center, Seoul, 110746, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 120-752, Korea, Republic of|Kyunghee University Medical Center, Seoul, 130702, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, 158-710, Korea, Republic of|The Catholic University of Korea, St.Vicent's Hospital, Suwon, 442723, Korea, Republic of|Wonju Christian Hospital, Wonju, 220701, Korea, Republic of|Academisch Medisch Centrum, Amsterdam, 1105 AZ, Netherlands|Albert Schweitzer Ziekenhuis, Dordrecht, 3318 AT, Netherlands|Ikazia Ziekenhuis, Rotterdam, 3083 AN, Netherlands|Christchurch Hospital, Christchurch, 8011, New Zealand|Dunedin Hospital, Dunedin, 9016, New Zealand|Waikato Hospital, Hamilton, 3204, New Zealand|Hutt Valley District Health Board, Lower Hutt, 5010, New Zealand|North Shore Hospital, Milford, 0620, New Zealand|SPZOZ Wojewodzki Szpital Zespolony im. J.Sniadeckiego, Bialystok, Poland|Niepubliczny Zaklad Opieki Zdrowotnej INTERMED, Czestochowa, 42-217, Poland|Elblaski Szpital Specjalistyczny z Przychodnia, Elblag, 82-300, Poland|Przychodnia Lekarska Nowy Chelm, Gdansk, 80-807, Poland|Economicus - NZOZ ALL-MEDICUS, Katowice, 40-660, Poland|Centrum Opieki Zdrowotnej Orkan Med, Ksawerow, 95-054, Poland|Niepubliczny Zaklad Opieki Zdrowotnej CENTRUM MEDYCZNE Szpital Swietej Rodziny, Lodz, 90-302, Poland|Instytut Medycyny Wsi, Lublin, 20-090, Poland|MEDICOR Centrum Medyczne, Rzeszow, 35-068, Poland|Niepubliczny Zaklad Opieki Zdrowotnej VIVAMED, Warsaw, 03-580, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Triclinium, Warszawa, 02-797, Poland|LexMedica Osrodek Badan Klinicznych, Wroclaw, 53-114, Poland|Regional Clinical Hospital, Krasnoyarsk, 660022, Russian Federation|SBEI HPE First Moscow State Medical University n.a. I.M. Sechenov of the MoH of the RF, Moscow, 119991, Russian Federation|Nizhegorodskaya Regional Clinical Hospital n.a. N.A. Semashko, Nizhniy Novgorod, 603126, Russian Federation|Novosibirsk State Medical University, Novosibirsk, 630084, Russian Federation|SBEI of HPE Omsk State Medical Academy Ministry of healthcare of RF, Omsk, 644043, Russian Federation|SEIHPE Rostov State Medical University of MoH of RF, Rostov on Don, 344022, Russian Federation|Russian Medical Military Academy na SMKirov, Saint Petersburg, 191163, Russian Federation|City Hospital 26, Saint Petersburg, 196247, Russian Federation|Medical Company Hepatolog, Samara, 443000, Russian Federation|Slovak Research Center, Ilava, 01901, Slovakia|Specializovana Nemocnica Svorada Zobor, Nitra, 94901, Slovakia|GASTRO I., s.r.o., Presov, 080 01, Slovakia|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, 76008, Ukraine|Ivano-Frankivsk City Clinical Hospital #1 Dep of Surgery SHEI Ivano-Frankivsk NMU, Ivano-Frankivsk, 76014, Ukraine|Institute of Therapy n.a. L.T. Maloy of NAMS of Ukraine, Kharkiv, 61039, Ukraine|Kyiv CCH #8 Dept of Gastroenterology P.L. Shupyk NMA of PGE, Kyiv, 04201, Ukraine|Order of the Red Star MMMCC MMCH Clinic of Gastroenterology, Kyiv, 1133, Ukraine|CNI Consultative and Diagnostic Center of Desnianskyi District of Kyiv, Kyiv, 2232, Ukraine|Lviv Regional Clinical Hospital, Lviv, 79010, Ukraine|Communal City Clinical Hospital of Ambulance, Dept of Therapy #1 D.Halytskyi Lviv NMU, Lviv, 79059, Ukraine|Vinnytsia Regional Clinical, Vinnytsia, 21018, Ukraine|Medical Clinical Research Center ""Health Clinic"", Vinnytsya, 21029, Ukraine|Municipal Institution Zaporizhzhia, Zaporizhzhia, 69600, Ukraine|Zaporizhzhya city multidisciplinary clinical hospital #9, Zaporizhzhya, 69065, Ukraine","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/16/NCT01647516/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/16/NCT01647516/SAP_001.pdf",NCT01647516,Inclusion Criteria:~* Ulcerative colitis (UC) confirmed on endoscopy~* Moderately to severely active UC (Mayo score 6-12)~Exclusion Criteria:~* Current use of anti-TNF agents,2012.0,3.0,0.9958894,3,199.0,1.0,COMPLETED,1.15,0.6,1,0
102609,130497,NCT01863771,A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.,https://clinicaltrials.gov/study/NCT01863771,,COMPLETED,The purpose of this study is to evaluate safety and effectiveness of golimumab in Japanese participants with moderately to severely active ulcerative colitis.,YES,"Colitis, Ulcerative",DRUG: Golimumab|OTHER: Placebo,"Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score, Clinical response was defined as a decrease from Induction-Week 0 in the Mayo score by greater than or equal to (\>=) 30 percent and \>=3 points, with a decrease in the rectal bleeding subscore of \>= 1 or a rectal bleeding subscore of 0 or 1. The Mayo score is the primary tool for assessing ulcerative colitis activity. The Mayo score consists of 4 subscores (stool frequency, rectal bleeding, findings of endoscopy, and physician's global assessment) which range from 0 to 3. The Mayo score is calculated as the sum of these 4 subscores and can range between 0 and 12. A score of 3 to 5 points indicates mildly active disease; a score of 6 to 10 indicates moderately active disease; and a score of 11 to 12 indicates severe disease., Up to Week 54","Number of Participants Who Achieved Clinical Remission at Both Maintenance-Week 30 and Week 54, Clinical remission (as measured by the Mayo score) was defined as a Mayo score of less than or equal to (\<=) 2 points, with no individual sub-score greater than (\>) 1., Weeks 30 and 54|Number of Participants With Mucosal Healing at Both Maintenance-Week 30 and Week 54, Mucosal healing is defined as an endoscopy subscore of 0 or 1, where 0 indicates normal or inactive disease and 1 indicates mild disease (erythema, decreased vascular pattern, mild friability). Endoscopy subscore is one of the 4 subscores of the Mayo score., Weeks 30 and 54",,Janssen Pharmaceutical K.K.,,ALL,"ADULT, OLDER_ADULT",PHASE3,144.0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",CR100937|CNTO148UCO3001,2013-03-15,2016-01-29,2016-01-29,2013-05-29,2017-02-17,2017-04-05,"Abiko, Japan|Chiba, Japan|Chikushinoshi, Japan|Fujiidera, Japan|Fukuoka, Japan|Fushimi, Japan|Hamamatsu, Japan|Hirosaki, Japan|Hiroshima, Japan|Ikeda, Japan|Izumiotsu, Japan|Izumo, Japan|Kagoshima, Japan|Kahoku, Japan|Kanazawa, Japan|Kochi, Japan|Kurume, Japan|Maebashi, Japan|Miyazaki, Japan|Nagasaki, Japan|Nagoya, Japan|Nishinomiya, Japan|Oita, Japan|Osaka, Japan|Saga, Japan|Sakura, Japan|Sapporo, Japan|Sendai, Japan|Suita, Japan|Sunto, Japan|Tokushima, Japan|Tokyo, Japan|Toyota, Japan|Tsukuba, Japan|Tsu, Japan|Wakayama, Japan|Yokkaichi, Japan|Yokohama, Japan",,NCT01863771,"Inclusion Criteria:~* Participants with ulcerative colitis diagnosed prior to screening~* Participants should have current treatment for ulcerative colitis with at least one of the following therapies: oral 5-aminosalicylates (5-ASAs), oral corticosteroids, 6-mercaptopurine (6-MP), or azathioprine (AZA)~* Participants must have a history of failure to respond to, or tolerate, at least 1 of the following therapies: oral 5-ASAs, oral corticosteroids, 6-MP, or AZA~* Participants must be ambulatory and have moderately to severely active ulcerative colitis confirmed during the screening sigmoidoscopy by a greater than or equal to 2 using the endoscopy subscore of the Mayo score~* Participants must have moderately to severely active ulcerative colitis, defined as a baseline Mayo score of 6 to 12, inclusive~Exclusion Criteria:~* Participants with ulcerative colitis limited to the rectum only or to less than 20 cm of the colon~* Participants with stoma~* Participants with fistula or history of fistula~* Participants who require, or required within the 2 months prior to screening, surgery for active gastrointestinal bleeding, peritonitis, intestinal obstruction, or intra-abdominal or pancreatic abscess requiring surgical drainage, or other conditions possibly confounding the evaluation of benefit from study agent treatment~* Participants with symptomatic colonic or small bowel obstruction, confirmed by objective radiographic or endoscopic evidence of a stricture with resulting obstruction",2013.0,3.0,0.99572486,4,144.0,1.0,COMPLETED,1.58,-0.044,0,0
38485,48899,NCT02289417,Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis,https://clinicaltrials.gov/study/NCT02289417,UC,COMPLETED,"The purpose of the study is to evaluate the clinical efficacy, safety and tolerability of apremilast (30 mg twice daily \[BID\] and 40 mg BID), compared with placebo, in participants with active Ulcerative Colitis (UC).",YES,Ulcerative Colitis,DRUG: Apremilast|DRUG: Placebo,"Percentage of Participants Who Achieved a Clinical Remission by Total Mayo Score (TMS) at Week 12, Clinical remission was defined as a total Mayo score ≤ 2 points, with no individual subscore exceeding 1 point. The TMS is an instrument designed to measure disease activity of UC. The Mayo score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease.

* Stool Frequency Subscore (SFS)
* Rectal Bleeding Subscore (RBS)
* Endoscopy Subscore
* Physician's Global Assessment (PGA). Two-sided 95% confidence intervals (CI) for the within-group percentages are based on the Wilson score method., Week 12","Percentage of Participants Who Achieved a Clinical Response by Total Mayo Score and the Reduction in the Rectal Bleeding Subscore at Week 12, Clinical response was defined as a decrease from baseline in the TMS of at least 3 points and at least 30%, along with a reduction in the rectal bleeding subscore (RBS) of at least 1 point or an absolute RBS of ≤ 1. The TMS is an instrument designed to measure disease activity of UC. The Mayo score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease.

* Stool Frequency Subscore (SFS)
* Rectal Bleeding Subscore
* Endoscopy Subscore
* Physician's Global Assessment (PGA)

Rectal bleeding (subscore 0-3) was defined as:

0 = No blood seen

1. = Streaks of blood with stool less than half the time
2. = Obvious blood with stool
3. = Blood alone passes Two-sided 95% CI for the within-group percentages are based on the Wilson score method., Week 12|Percentage of Participants Who Achieved an Endoscopic Remission at Week 12, An endoscopic remission was defined as a Mayo endoscopic subscore (MES) of 0 at Week 12.

The MES subscore findings were defined as:

0 = Normal or inactive disease

1. = Mild Disease (erythema, decreased vascular pattern, mild friability)
2. = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions)
3. = Severe Disease (spontaneous bleeding, ulceration)

The endoscopy subscores consisted of findings that were centrally read through proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method., Week 12|Percentage of Participants Who Achieved an Endoscopic Response at Week 12, An endoscopic response is defined as a decrease from baseline of at least 1 point in the MES at Week 12. The Mayo endoscopy subscore findings were defined as:

0 = Normal or inactive disease

1. = Mild Disease (erythema, decreased vascular pattern, mild friability)
2. = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions) 3 = Severe Disease (spontaneous bleeding, ulceration).

The endoscopy subscores consisted of findings that were centrally read through proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method., Week 12|Percentage of Participants Who Achieved a Rectal Bleeding Subscore (RBS) of ≤ 1 at Week 12, The RBS was measured as:

0 = No blood seen

1. = Streaks of blood with stool less than half the time
2. = Obvious blood with stool most of the time
3. = Blood alone passes

The daily bleeding score represents the most severe bleeding of the day. Two-sided 95% CI for the within-group proportions are based on the Wilson score method., Week 12|Percentage of Participants Who Achieved Clinical Remission in the Modified Mayo Subscore (MMS) at Week 12, Clinical remission was defined as a modified Mayo score of ≤ 2, with no individual subscore \> 1, at Week 12. The MMS was based on a modification of the total Mayo score (TMS) which included the stool frequency, rectal bleeding, and endoscopic subscores of the TMS and excluded the Physician's Global Assessment (PGA) subscore, since this was a global measure that is subjective in nature. The MMS ranges from 0 to 9 points with higher scores indicating greater disease severity. The endoscopy subscores was centrally reviewed. Two-sided confidence intervals for the within-group percentage were based on the Wilson score method., Week 12|Percentage of Participants Who Achieved Clinical Response in the Modified Mayo Subscore (MMS) at Week 12, Clinical response in the MMS was defined as a decrease from baseline in the MMS of at least 2 points and at least 25%, along with a reduction in the RBS of at least 1 point or an absolute RBS ≤ 1. The MMS was based on the stool frequency, rectal bleeding, and endoscopic subscores of the TMS and excluded the PGA subscore. The MMS ranges from 0 to 9 points with higher scores indicating greater disease severity.

The RBS was measured as:

0 = No blood seen

1. = Streaks of blood with stool less than half the time
2. = Obvious blood with stool most of the time
3. = Blood alone passes

The daily bleeding score represents the most severe bleeding of the day. The endoscopy subscores was centrally reviewed. Two-sided confidence intervals for the within-group percentage were based on the Wilson score method., Week 12|Percentage of Participants Who Achieved Clinical Remission in the Partial Mayo Subscore (PMS) With no Individual Subscore >1 at Week 8, Clinical remission in the partial Mayo subscore was defined as a PMS of 2 points or lower, with no individual subscore \>1. The PMS is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores:

Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

Two-sided 95% CI for the within-group proportions are based on the Wilson score method., Week 8|Percentage of Participants Who Achieved Clinical Response in the Partial Mayo Subscore at Week 8, Clinical response in the PMS was defined as a decrease from baseline in PMS of at least 2 points and at least 25%, with an accompanying decrease in the RBS of at least 1 point or an absolute RBS of 0 or 1. The PMS score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores:

Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

Two-sided 95% CI for the within-group proportions are based on the Wilson score method., Week 8|The Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs) During the Placebo-Controlled Phase, A TEAE was defined as any adverse event (AE) occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain, From the first dose of investigational product (IP) and no later than 28 days after the last dose of IP for those who had completed the study or discontinued (D/C) early; maximum duration of exposure to treatment was 12.00 weeks|The Number of Participants Who Discontinued Apremilast Due to Treatment Emergent Adverse Events During the Placebo-Controlled Period, A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain., From the first dose of IP and no later than 28 days after the last dose of IP for those who had completed the study or discontinued early; median duration of exposure to treatment was 12.00 weeks|The Number of Participants Who Experienced TEAEs During the Apremilast (APR) Exposure Period (Active Treatment Phase) Through Week 52, A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain, From first dose of IP and no later than 28 days after last dose of IP for those who completed the active treatment phase or D/C early; median duration of exposure = 41.00, 44.15 and 40.00 weeks respectively for 30 mg, 40 mg and 30 mg/40 mg APR arms|The Number of Participants Who Experienced TEAEs During Week 52 to Week 104 (Extension Phase), A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain, From the first dose of IP at Week 52 and no later than 28 days after the last dose of IP for those who completed the study or had discontinued early; median exposure of apremilast for the total apremilast group was 52 weeks.",,Amgen,,ALL,"ADULT, OLDER_ADULT",PHASE2,170.0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",CC-10004-UC-001|2014-002981-64,2015-01-08,2017-09-25,2019-06-03,2014-11-13,2018-10-29,2020-05-07,"Digestive Health Specialists of The Southeast, Dothan, Alabama, 36305, United States|Southern California Research Institute Medical Group, Inc., Los Angeles, California, 90045, United States|Connecticut Clinical Research Foundation, Bristol, Connecticut, 06010, United States|Consultants for Clinical Research of South Florida, Boynton Beach, Florida, 33426, United States|Avail Clinical Research, LLC, DeLand, Florida, 32720, United States|Precision Clinical Research, LLC, Lauderdale Lakes, Florida, 33319, United States|Pharmax Research Clinic, Inc., Miami, Florida, 33126, United States|Gastroenterology Group of Naples, Naples, Florida, 34102, United States|Advanced Medical Research Center, Port Orange, Florida, 32127, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242, United States|University of Louisville, Louisville, Kentucky, 40202, United States|UMass Medical Center, Worcester, Massachusetts, 01655, United States|Clinical Research Institute of Michigan, LLC, Chesterfield, Michigan, 48047, United States|Center for Digestive Health Research, Troy, Michigan, 48098, United States|Gastrointestinal Associates PA, Flowood, Mississippi, 39232, United States|NYU Langone Long Island Clinical Research Associates, Great Neck, New York, 11021, United States|Consultants for Clinical Research, Cincinnati, Ohio, 45219, United States|Quality Medical Research, Nashville, Tennessee, 37211, United States|Digestive Research Center/ Gastroenterology Consultants of San Antonio, Live Oak, Texas, 78233, United States|Digestive Health Specialist of Tyler, Pasadena, Texas, 77505, United States|San Antonio Gastroenterology, San Antonio, Texas, 78229, United States|University of Utah, Salt Lake City, Utah, 84132, United States|Harborview Medical Center, Seattle, Washington, 98104, United States|University of Washington Medical Center, Seattle, Washington, 98195, United States|Concord Repatriation General Hospital, Concord, New South Wales, 2139, Australia|Liverpool Hospital, Liverpool, New South Wales, 2170, Australia|Mater Adult Hospital, South Brisbane, Queensland, 4101, Australia|Footscray Hospital, Footscray, Victoria, 3011, Australia|Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia|Multiprofile Hospital for Active Treatment Kaspela, Plovdiv, 4002, Bulgaria|Medical Center Asklepion - Humane Medicine Research EOOD, Sofia, 1303, Bulgaria|University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic Sofia, Sofia, 1407, Bulgaria|University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD, Sofia, 1431, Bulgaria|University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD, Sofia, 1527, Bulgaria|Clinic of Gastroenterology, Sofia, 1784, Bulgaria|Multiprofile Hospital for Active Treatment Sveta Marina EAD, Varna, 9010, Bulgaria|Winnipeg Regional Health Authority - Health Sciences Centre, Winnipeg, Manitoba, R3A 1R9, Canada|Hamilton Health Sciences Corporation, McMaster University Medical Centre, Hamilton, Ontario, L8N 3Z5, Canada|Fakultni nemocnice u sv Anny v Brne, Brno, 656 91, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, 500 05, Czechia|Hepato-Gastroenterologie HK, s. r. o., Hradec Králové, 500 12, Czechia|Nemocnice Slany, Slany, 274 01, Czechia|Amiens University Hospital, Amiens, 80054, France|Hopital Beaujon, Clichy, 92110, France|CHRU Nantes, Nantes, 602 00, France|CHU de Nice Archet I, Nice, 06202, France|Centre Hospitalier Lyon Sud, Pierre Bénite, 69495, France|Centre Hospitalier Universitaire de Saint Etienne, Saint Priest en Jarez, 42055, France|CHRU Nancy, Vandoeuvre les Nancy, 54511, France|DRK Kliniken Berlin Westend, Berlin, 14050, Germany|Crohn-Colitis-Centre Rhein-Main, Frankfurt, 60594, Germany|Universitatsklinikum Schleswig-Holstein, Keil, 24105, Germany|Gastroenterologische Praxis Minden, Minden, 32423, Germany|Pannónia Magánorvosi Centrum Kft., Budapest, 1136, Hungary|ENDOMEDIX Kft., Budapest, 1139, Hungary|Vasútegészségügyi Nonprofit Kiemelten Közhasznú Kft. Debreceni Egészségügyi Központja, Debrecen, 4025, Hungary|Karolina Korhaz Rendelointezet, Mosonmagyaróvár, 9200, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged, 6720, Hungary|Tolna Megyei Balassa Janos Korhaz, Szekszárd, 7100, Hungary|Javorszky Odon Korhaz, Vác, 2600, Hungary|Azienda Ospedaliero Universitaria Di Bologna Policlinico Sorsola Malpighi, Bologna, 40138, Italy|IRCCS - Istituo Clinico Humanitas - Humanitas Cancer Center, Milan, 20089, Italy|Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, 90146, Italy|Fondazione PTV Policlinico Tor Vergata, Roma, 00133, Italy|Complesso Integrato Columbus, Roma, 00168, Italy|Universitair Medisch Centrum Groningen, Groningen, 9713 GZ, Netherlands|Ikazia Ziekenhuis, Rotterdam, 3083 AN, Netherlands|Auckland City Hospital, Auckland, 1023, New Zealand|Christchurch Hospital, Christchurch, 8011, New Zealand|Dunedin Hospital, Dunedin, 9016, New Zealand|Waikato hospital, Hamilton, 3204, New Zealand|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, 15-276, Poland|Osrodek Badan Klinicznych CLINSANTE S.C., Bydgoszcz, 85-794, Poland|Centrum Medyczne sw. Lukasza, Czestochowa, 42 202, Poland|Economicus - NZOZ ALL-MEDICUS, Katowice, 40 659, Poland|Endoskopia Sp. z o.o., Sopot, 81-756, Poland|Sonomed Sp. z o.o., Szczecin, 71-685, Poland|Gastromed Kopon Zmudzinski i Wspolnicy Sp. j. Specjalistyczne Centrum Gastrologii i Endoskopii Spec. Gabinety Lekarskie, Torun, 40 659, Poland|Centrum Zdrowia Matki, Dziecka i Mlodziezy, Warsaw, 00-632, Poland|Niepubliczny Zaklad Opieki Zdrowotnej VIVAMED, Warszawa, 03-563, Poland|Lexmedica Drubajlo Hanna, Wroclaw, 03-580, Poland|Ars Medica, Wroclaw, 53-333, Poland|Republican Clinical Hospital, Kazan, 420064, Russian Federation|Stolitsa-Medikl, LLC, Moscow, 115088, Russian Federation|SEIHPE Rostov State Medical University of MoH of RF, Rostov on Don, 344022, Russian Federation|Regional Clinical Hospital, Saratov, 410053, Russian Federation|Russian Medical Military Academy na SMKirov, St Petersburg, 129329, Russian Federation|Regional Clinical Hospital, Gastroenterology department, State Higher Education Institute Ivano-Frankivsk National Medical University, Ivano-Frankivsk, 58001, Ukraine|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, 76008, Ukraine|Ivano-Frankivsk Central City Clinical Hospital, Ivano-Frankivsk, 76018, Ukraine|Kharkiv City Clinical Hospital 2, Kharkiv, 61037, Ukraine|Private Enterprise Private Manufacture Company Acinus, Kirovograd, 25006, Ukraine|Kremenchuk City Hospital # 1 n.a O.T.Bohaievskyi, Kremenchuk, 39617, Ukraine|Lviv Emergency Clinical Hospital, Therapeutics Department No. 1, Lviv, 79059, Ukraine|Municipal Institution Odesa Regional Clinical Hospital, Odesa, 65025, Ukraine|Central City Clinical Hospital, Uzhgorod, 88000, Ukraine|Vinnytsia Regional Clinical Hospital n a M I Pyrohov, Vinnytsia, 21018, Ukraine|Municipal Institution Zaporizhzhia, Zaporizhzhia, 69600, Ukraine","Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/17/NCT02289417/SAP_001.pdf|Study Protocol, https://cdn.clinicaltrials.gov/large-docs/17/NCT02289417/Prot_002.pdf",NCT02289417,"Inclusion Criteria:~Subjects must satisfy the following criteria to be enrolled in the study:~* Male or female aged 18 and over at the time of signing the informed consent.~* Must understand and voluntarily sign an informed consent form prior to any study related assessments/procedures being conducted.~* Diagnosis of ulcerative colitis (UC) with a duration of at least 3 months prior to the Screening Visit..~* Total Mayo Score (TMS) ≥ 6 to ≤ 11 (range: 0-12) at baseline, prior to randomization in the study.~* Endoscopic subscore ≥ 2 (range: 0-3) on the Mayo score prior to randomization in the study.~* Subjects must have had a therapeutic failure, been intolerant to, or have a contraindication to, at least one of the following: oral aminosalicylates (ie, 5-aminosalicylic acid \[5-ASA\] compounds or sulfasalazine \[SSZ\]), budesonide, systemic corticosteroids, or immunosuppressants (eg, 6-mercaptopurine \[6-MP\], azathioprine \[AZA\], or methotrexate \[MTX\]).~Exclusion Criteria:~The presence of any of the following will exclude a subject from enrollment:~* Diagnosis of Crohn's disease, indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis or diverticular disease-associated colitis.~* Ulcerative colitis restricted to the distal 15 cm or less (eg, ulcerative proctitis).~* Subjects who have had surgery as a treatment for UC or who, in the opinion of the Investigator, are likely to require surgery for UC during the study.~* Clinical signs suggestive of fulminant colitis or toxic megacolon.~* Prior use of any tumor necrosing factor (TNF) inhibitor (or any biologic agent).~* Prior use of mycophenolic acid, tacrolimus, sirolimus, cyclosporine or thalidomide.~* Use of intravenous (IV) corticosteroids within 2 weeks of the Screening Visit.~* Use of immunosuppressants (AZA, 6-MP or MTX) within 8 weeks of the Screening Visit.~* Use of topical treatment with 5-ASA or corticosteroid enemas or suppositories within 2 weeks of the Screening Visit.~* History of any clinically significant neurological, renal, hepatic, gastrointestinal, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease, or any other medical condition that, in the investigator's opinion, would preclude participation in the study.",2015.0,2.0,0.99556196,5,170.0,1.0,COMPLETED,2.19,-0.067,1,0
48769,62006,NCT03759041,A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis,https://clinicaltrials.gov/study/NCT03759041,ECO-RESET,TERMINATED,"A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to-Moderate Ulcerative Colitis",YES,Ulcerative Colitis,DRUG: Vancomycin Pre-Treatment|DRUG: Placebo for Vancomycin Pre-Treatment|DRUG: SER-287|DRUG: Placebo for SER-287,"Clinical Remission (Count of Participants), Clinical remission for the induction treatment period:

* Stool Frequency subscore = 0 or 1, with at least 1-point decrease from baseline
* Rectal Bleeding subscore = 0
* Endoscopic subscore = 0 or 1 on modified Mayo Score, with at least 1-point decrease from baseline
* No occurrence of UC Flare during the treatment period

Clinical remission was measured using 3 components of the modified Mayo Score (stool frequency, rectal bleeding and endoscopic subscore), a measure of UC disease activity. These 3 components are each graded from 0 to 3, and are summed together for a composite score, with a higher overall score indicating more severe disease (0 = no disease; 9 = worst disease). The modified Mayo endoscopic subscore excludes friability from an endoscopic subscore of 1., After 10 weeks of induction dosing","Endoscopic Improvement (Count of Participants), Endoscopic subscore decrease from baseline of at least 1 point, as assessed by flexible sigmoidoscopy or colonoscopy.

Endoscopic improvement was measured using the modified Mayo Score endoscopic subscore, graded from 0 to 3, with higher scores indicating more severe disease. The modified Mayo endoscopic subscore excludes friability from an endoscopic subscore of 1., After 10 weeks of induction dosing",,"Seres Therapeutics, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,203.0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",SERES-201,2018-12-19,2021-05-28,2021-10-13,2018-11-29,2022-06-21,2022-08-12,"(Investigator site), Phoenix, Arizona, 85018, United States|(Investigator site), North Little Rock, Arkansas, 72117, United States|(Investigator site), La Jolla, California, 92037, United States|(Investigator site), Lancaster, California, 93534, United States|(Investigator site), Los Angeles, California, 90067, United States|(Investigator site), Mountain View, California, 94040, United States|(Investigator site), San Diego, California, 92103, United States|(Investigator site), San Diego, California, 92123, United States|(Investigator site), Wheat Ridge, Colorado, 80033, United States|(Investigator site), Danbury, Connecticut, 06810, United States|(Investigator site), Hamden, Connecticut, 06518, United States|(Investigator site), Boca Raton, Florida, 33487, United States|(Investigator site), Clearwater, Florida, 33762, United States|(Investigator site), Crystal River, Florida, 34429, United States|(Investigator site), Fort Lauderdale, Florida, 33308, United States|(Investigator site), Hialeah, Florida, 33012, United States|(Investigator site), Jacksonville, Florida, 32256, United States|(Investigator site), Miami, Florida, 33136, United States|(Investigator site), Miami, Florida, 33176, United States|(Investigator site), Naples, Florida, 34102, United States|(Investigator site), Ocala, Florida, 34474, United States|(Investigator site), Orlando, Florida, 32803, United States|(Investigator site), Pompano Beach, Florida, 33060, United States|(Investigator site), Port Orange, Florida, 32127, United States|(Investigator site), Tampa, Florida, 33609, United States|(Investigator site), Athens, Georgia, 30607, United States|(Investigator site), Atlanta, Georgia, 30322, United States|(Investigator site), Marietta, Georgia, 30060, United States|(Investigator site), Chicago, Illinois, 60611, United States|(Investigator site), Chicago, Illinois, 60612, United States|(Investigator site), Chicago, Illinois, 60637, United States|(Investigator site), Indianapolis, Indiana, 46202, United States|(Investigator site), Lexington, Kentucky, 40536, United States|(Investigator site), Lake Charles, Louisiana, 70601, United States|(Investigator site), Metairie, Louisiana, 70006, United States|(Investigator site), Monroe, Louisiana, 71201, United States|(Investigator site), New Orleans, Louisiana, 70121, United States|(Investigator site), Shreveport, Louisiana, 71105, United States|(Investigator site), Baltimore, Maryland, 21287, United States|(Investigator site), Glen Burnie, Maryland, 21208, United States|(Investigator site), Ann Arbor, Michigan, 48109, United States|(Investigator site), Farmington Hills, Michigan, 48334, United States|(Investigator site), Rochester, Minnesota, 55905, United States|(Investigator site), Bridgeton, Missouri, 63044, United States|(Investigator site), Creve Coeur, Missouri, 63141, United States|(Investigator site), Las Vegas, Nevada, 89123, United States|(Investigator site), Reno, Nevada, 89511, United States|(Investigator site), Lebanon, New Hampshire, 03756, United States|(Investigator site), Great Neck, New York, 11021, United States|(Investigator site), Hartsdale, New York, 10530, United States|(Investigator site), New York, New York, 10016, United States|(Investigator site), New York, New York, 10032, United States|(Investigator site), Asheville, North Carolina, 28801, United States|(Investigator site), Chapel Hill, North Carolina, 27599, United States|(Investigator site), Durham, North Carolina, 27710, United States|(Investigator site), Raleigh, North Carolina, 27612, United States|(Investigator site), Winston-Salem, North Carolina, 27103, United States|(Investigator site), Winston-Salem, North Carolina, 27157, United States|(Investigator site), Cincinnati, Ohio, 45219, United States|(Investigator site), Oklahoma City, Oklahoma, 73104, United States|(Investigator site), Columbia, South Carolina, 29203, United States|(Investigator site), Greenville, South Carolina, 29615, United States|(Investigator site), Memphis, Tennessee, 38119, United States|(Investigator site), Nashville, Tennessee, 37212, United States|(Investigator site), Bedford, Texas, 76022, United States|(Investigator site), Fort Sam Houston, Texas, 78219, United States|(Investigator site), Houston, Texas, 77030, United States|(Investigator site), Houston, Texas, 77043, United States|(Investigator site), Houston, Texas, 77090, United States|(Investigator site), McAllen, Texas, 78504, United States|(Investigator site), San Antonio, Texas, 78229, United States|(Investigator site), Temple, Texas, 76508, United States|(Investigator site), Ogden, Utah, 84405, United States|(Investigator site), Salt Lake City, Utah, 84124, United States|(Investigator site), Leesburg, Virginia, 20176, United States|(Investigator site), Lynchburg, Virginia, 24502, United States|(Investigator site), Reston, Virginia, 20191, United States|(Investigator site), Richmond, Virginia, 23249, United States|(Investigator site), Spokane, Washington, 99202, United States|(Investigator site), Madison, Wisconsin, 53792, United States|(Investigator site), Milwaukee, Wisconsin, 53215, United States|(Investigator site), Edmonton, Alberta, T6G 2L7, Canada|(Investigator site), Edmonton, Alberta, T6L 6K3, Canada|(Investigator site), New Westminster, British Columbia, V3L 3W4, Canada|(Investigator site), Bridgewater, Ontario, B4V 3K9, Canada|(Investigator site), Lindsay, Ontario, K9V 5G6, Canada|(Investigator site), London, Ontario, N6A 5A5, Canada|(Investigator site), London, Ontario, N6A 5W9, Canada|(Investigator site), Sudbury, Ontario, P3C 5K6, Canada|(Investigator site), Toronto, Ontario, M5T 3A9, Canada|(Investigator site), Vaughan, Ontario, L4L 4Y7, Canada|(Investigator site), Greenfield Park, Quebec, J4V 2H1, Canada|(Investigator site), Saskatoon, Saskatchewan, S7N 0W8, Canada","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/41/NCT03759041/Prot_000.pdf|Statistical Analysis Plan: Clinical SAP, https://cdn.clinicaltrials.gov/large-docs/41/NCT03759041/SAP_001.pdf|Statistical Analysis Plan: Microbiome SAP, https://cdn.clinicaltrials.gov/large-docs/41/NCT03759041/SAP_002.pdf",NCT03759041,"Inclusion Criteria:~* Documented diagnosis of UC at least three months prior to screening, and with a minimum disease extent of 15 cm from the anal verge~* Active mild-to-moderate UC~* Inadequate response to, loss of response to, or intolerance of, at least one of the following conventional therapies: 5-ASA compounds, corticosteroids, 6-mercaptopurine (6-MP) or azathioprine (AZA), anti-TNFα, anti-integrin or tofacitinib~Exclusion Criteria:~* Known history of Crohn's disease~* No previous history of treatment for UC (treatment-naïve)~* Subjects on steroid medication who are unable to have steroids tapered and be completely off steroids at least two weeks prior to screening~* Unable to stop steroid enemas or suppositories, or 5-ASA enemas or suppositories, at least two weeks prior to screening~* Subjects who have received any investigational or approved biologic therapy within eight weeks or five half-lives prior to screening (whichever is longer)~* Subjects who have received any investigational or approved non-biologic therapy, except for those specifically listed in the Permitted Concomitant Medications, for the treatment of underlying disease, within 30 days or five half-lives prior to screening (whichever is longer)~* Major gastrointestinal surgery (not including appendectomy or cholecystectomy) within two months before screening, or any history of total colectomy",2018.0,3.0,0.9955056,6,203.0,1.0,TERMINATED,1.79,-0.067,1,0
66446,84478,NCT04074590,"Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis",https://clinicaltrials.gov/study/NCT04074590,,TERMINATED,"The purpose of the study was to assess preliminary efficacy, safety, and tolerability of LYS006 in adult patients with mild to moderate ulcerative colitis and to determine if LYS006 has an adequate clinical profile for further development in this indication.",YES,"Colitis, Ulcerative",DRUG: LYS006|DRUG: Placebo,"Clinical Remission Rate at the End of the Study Treatment, The Mayo score is an instrument designed to measure activity of ulcerative colitis. The Mayo score comprises of four sub scores: stool frequency, rectal bleeding, endoscopic findings and the Physician's Global Assessment (PhGA). Each sub score is graded from 0 to 3 with higher scores indicating more severe disease. The full Mayo score is the sum of four sub scores, ranging from 0 to 12. Clinical remission is defined as a full Mayo score of 2 points or lower, with no individual subscore exceeding one point. The clinical remission rate is expressed as percentage of participants. The binary endpoint of clinical remission rate (Yes/No) at the EoT visit was modelled with binomial distribution and analyzed via the Bayesian approach with baseline total Mayo score and treatment group as explanatory variables, to compare the remission rates between the LYS006 and placebo groups., Week 8","Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of participants with treatment emergent AEs, AEs led to study treatment discontinuation, SAEs and SAEs led to study treatment discontinuation., Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of approximately 86 days.",,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE2,23.0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",CLYS006X2202|2019-003113-34,2020-02-03,2022-11-07,2022-11-07,2019-08-30,2023-11-09,2024-06-20,"Novartis Investigative Site, Sofia, 1612, Bulgaria|Novartis Investigative Site, Praha 19, Czech Republic, 19000, Czechia|Novartis Investigative Site, Zlin, Czech Republic, 762 75, Czechia|Novartis Investigative Site, Berlin, 10629, Germany|Novartis Investigative Site, Nowy Targ, Malopolskie, 34-400, Poland|Novartis Investigative Site, Warszawa, Mazowieckie, 00-728, Poland|Novartis Investigative Site, Poznan, 60 529, Poland|Novartis Investigative Site, Novosibirsk, 630007, Russian Federation|Novartis Investigative Site, Kosice, 04013, Slovakia","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/90/NCT04074590/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/90/NCT04074590/SAP_001.pdf",NCT04074590,"Key Inclusion Criteria:~* Male and female subjects 18-75 years of age with an established diagnosis of ulcerative colitis at least 3 months prior to screening are eligible for the study.~* Patients must have active disease with a full Mayo Score between 5 and 10 (inclusive) with an endoscopy score of 2 or 3; rectal bleeding and stool frequency scores 1 to 3 and a physician's global assessment of 1 or 2.~* Patients must have responded inadequately to conventional therapy with oral 5-ASA prior to screening.~Key Exclusion Criteria:~* Has previous diagnosis with Crohn's disease, indeterminate colitis, microscopic colitis or acute diverticulitis based on medical history.~* History of toxic megacolon, abdominal abscess, symptomatic colonic stricture, or stoma; history or is at risk of colectomy.~* Treatment with biologics within 3 months or 5 half-lives (whichever is longer) prior to screening endoscopy, non-biologics advanced therapies within 4 weeks prior to screening endoscopy, systemic immunosuppressant or immunomodulator within 6 week, topical treatment with 5-ASA or steroids within 2 weeks prior to screening endoscopy",2020.0,2.0,0.99545866,7,23.0,1.0,TERMINATED,2.58,0.153,0,0
4474,5670,NCT03653026,A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis,https://clinicaltrials.gov/study/NCT03653026,U-Accomplish,COMPLETED,The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo in inducing clinical remission (per Adapted Mayo score) in participants with moderately to severely active ulcerative colitis (UC).,YES,Ulcerative Colitis (UC),DRUG: Placebo|DRUG: Upadacitinib,"Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8, The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:

1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).
2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).
3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).

The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease.

Clinical remission is defined as an Adapted Mayo score ≤ 2, with SFS ≤ 1 and not higher than Baseline, RBS of 0, and endoscopic subscore ≤ 1., Week 8","Percentage of Participants With Endoscopic Improvement at Week 8, Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration)., Week 8|Percentage of Participants With Endoscopic Remission at Week 8, Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration)., Week 8|Percentage of Participants Who Achieved Clinical Response Per Adapted Mayo Score at Week 8, The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:

1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).
2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).
3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration).

The overall Adapted Mayo score ranges from 0 to 9 with higher scores representing more severe disease.

Clinical response per the Adapted Mayo Score is defined as a decrease in Adapted Mayo score ≥ 2 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1., Week 8|Percentage of Participants Who Achieved Clinical Response Per Partial Adapted Mayo Score at Week 2, The Partial Adapted Mayo Score is a composite score of UC disease activity based on the following 2 subscores:

1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).
2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).

The overall Partial Adapted Mayo score ranges from 0 to 6 with higher scores representing more severe disease.

Clinical response per Partial Adapted Mayo Score is defined as a decrease in Partial Adapted Mayo score ≥ 1 point and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1., Week 2|Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 8, Histologic endoscopic mucosal improvement is defined as an endoscopic subscore of 0 or 1 and a Geboes score ≤ 3.1.

The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration).

The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration., Week 8|Percentage of Participants Who Reported No Bowel Urgency at Week 8, Bowel urgency was assessed by participants in a subject diary completed once a day., Week 8|Percentage of Participants Who Reported No Abdominal Pain at Week 8, Abdominal pain was assessed by participants in a subject diary completed once a day., Week 8|Percentage of Participants Who Achieved Histologic Improvement at Week 8, Histologic improvement is defined as a decrease from Baseline in Geboes score. The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration., Week 8|Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 8, The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement., Baseline (Week 0) to Week 8|Percentage of Participants Who Achieved Mucosal Healing at Week 8, Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration).

The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration., Week 8|Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 8, The FACIT fatigue questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. Each question is answered on a 5-point Likert scale: 0 (not at all); 1 (a little bit); 2 (somewhat); 3 (quite a bit); and 4 (very much). The total score ranges from 0 to 52, where higher scores represent less fatigue, and a positive change from Baseline indicates improvement., Baseline (Week 0) to Week 8",,AbbVie,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,522.0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",M14-675|2016-000642-62,2018-12-06,2021-01-14,2021-01-14,2018-08-31,2021-11-26,2022-03-02,"East View Medical Research, LLC /ID# 216933, Mobile, Alabama, 36606, United States|CB Flock Research Corporation /ID# 206094, Mobile, Alabama, 36608, United States|Arizona Arthritis & Rheumatology Research, PLLC /ID# 211030, Sun City, Arizona, 85306, United States|Digestive Disease Consultants, A Division of Arizona Digestive Health, P.C /ID# 211887, Tempe, Arizona, 85284-2604, United States|University of Arizona /ID# 208856, Tucson, Arizona, 85724, United States|Citrus Valley Gastroenterology /ID# 205627, Covina, California, 91722-3797, United States|Care Access Research /ID# 217003, Huntington Beach, California, 92648-5994, United States|Moore UC San Diego Cancer Center /ID# 204919, La Jolla, California, 92093, United States|United Medical Doctors /ID# 207867, Los Alamitos, California, 90720-3309, United States|TLC Clinical Research Inc /ID# 216831, Los Angeles, California, 90048, United States|Gastrointestinal Biosciences Clinical Trials, LLC /ID# 205314, Los Angeles, California, 90067-2001, United States|Facey Medical Foundation /ID# 205301, Mission Hills, California, 91345, United States|United Medical Doctors - Murrieta /ID# 205313, Murrieta, California, 92563, United States|InSite Digestive Health Care - Oxnard /ID# 205628, Oxnard, California, 93030, United States|Inland Empire Clinical Trials, LLC /ID# 216164, Rialto, California, 92377, United States|San Diego Clinical Trials /ID# 212122, San Diego, California, 92120, United States|Medical Assoc Research Grp /ID# 205626, San Diego, California, 92123, United States|Delta Waves, Inc. /ID# 206170, Colorado Springs, Colorado, 80918, United States|Western States Clinical Res /ID# 206091, Wheat Ridge, Colorado, 80033-2896, United States|Western Connecticut Medical Group /ID# 208290, Danbury, Connecticut, 06810-6000, United States|Gastroenterology Center of CT /ID# 208291, Hamden, Connecticut, 06518, United States|Gastro Florida /ID# 206174, Clearwater, Florida, 33756, United States|Universal Axon Clinical Research /ID# 213462, Doral, Florida, 33166, United States|Palmetto Research, LLC /ID# 208293, Hialeah, Florida, 33016, United States|Nature Coast Clinical Research - Inverness /ID# 206087, Inverness, Florida, 34452-4717, United States|Encore Borland-Groover Clinical Research /Id# 208128, Jacksonville, Florida, 32256, United States|Cfagi Llc /Id# 207995, Maitland, Florida, 32751-6108, United States|University of Miami /ID# 215445, Miami, Florida, 33136, United States|Coral Research Clinic /ID# 208292, Miami, Florida, 33186-4643, United States|Advanced Research Institute, Inc /ID# 206077, New Port Richey, Florida, 34653, United States|Endoscopic Research, Inc. /ID# 207360, Orlando, Florida, 32803, United States|Omega Research Consultants /ID# 206066, Orlando, Florida, 32810, United States|Clinical Research Trials of Florida, Inc. /ID# 206068, Tampa, Florida, 33607, United States|University of South Florida /ID# 214495, Tampa, Florida, 33612, United States|AdventHealth Tampa /ID# 207363, Tampa, Florida, 33613-4680, United States|Gastroenterology Associates of Central Georgia, LLC /ID# 216940, Macon, Georgia, 31201, United States|Infinite Clinical Trials /ID# 215343, Riverdale, Georgia, 30274, United States|Atlanta Gastroenterology Spec /ID# 206173, Suwanee, Georgia, 30024, United States|Next Innovative Clinical Research - Chicago /ID# 217324, Chicago, Illinois, 60605-2168, United States|The University of Chicago Medical Center /ID# 206172, Chicago, Illinois, 60637-1443, United States|Carle Foundation Hospital /ID# 207397, Effingham, Illinois, 62401, United States|MediSphere Medical Research Center /ID# 206073, Evansville, Indiana, 47714-8011, United States|Indianapolis Gastroenterology /ID# 206381, Indianapolis, Indiana, 46237, United States|University of Iowa Hospitals and Clinics /ID# 206167, Iowa City, Iowa, 52242, United States|Cotton-O'Neil Clinical Res Ctr /ID# 206175, Topeka, Kansas, 66606, United States|Tri-State Gastroenterology /ID# 206124, Crestview Hills, Kentucky, 41017, United States|Houma Digestive Health Special /ID# 206176, Houma, Louisiana, 70360, United States|Louisana Research Center, LLC /ID# 206064, Shreveport, Louisiana, 71105-6800, United States|Gastro Center of Maryland /ID# 206883, Columbia, Maryland, 21045, United States|University of Michigan Health Systems /ID# 206918, Ann Arbor, Michigan, 48109, United States|Huron Gastroenterology Assoc /ID# 205109, Ann Arbor, Michigan, 48197, United States|Clin Res Inst of Michigan, LLC /ID# 207078, Chesterfield, Michigan, 48047, United States|Revival Research Institute, LLC /ID# 207282, Southfield, Michigan, 48034-1659, United States|Center for Digestive Health /ID# 207080, Troy, Michigan, 48098-6363, United States|Mayo Clinic /ID# 205645, Rochester, Minnesota, 55905-0001, United States|University of Mississippi Medical Center /ID# 213116, Jackson, Mississippi, 39216-4500, United States|Southern Therapy and Advanced Research (STAR) LLC /ID# 206069, Jackson, Mississippi, 39216, United States|Las Vegas Medical Research /ID# 206814, Las Vegas, Nevada, 89113, United States|AGA Clinical Research Associates, LLC /ID# 206880, Egg Harbor Township, New Jersey, 08234, United States|Atlantic Digestive Health Inst /ID# 208748, Morristown, New Jersey, 07960, United States|Rutgers Robert Wood Johnson /ID# 207382, New Brunswick, New Jersey, 08901, United States|University of New Mexico Department of Internal Medicine /ID# 214397, Albuquerque, New Mexico, 87131-0001, United States|Advantage Clinical Trials /ID# 206082, Bronx, New York, 10468, United States|NY Scientific /ID# 206080, Brooklyn, New York, 11235, United States|NYU Langone Long Island Clinical Research Associates /ID# 206079, Lake Success, New York, 11042, United States|DiGiovanna Institute for Medical Education & Research /ID# 206885, North Massapequa, New York, 11758, United States|Premier Medical Group - GI Division /ID# 206097, Poughkeepsie, New York, 12601, United States|Gastro Group of Rochester /ID# 206881, Rochester, New York, 14618-5703, United States|Richmond University Medical Center /ID# 213185, Staten Island, New York, 10310-1664, United States|Digestive Health Partners, P.A /ID# 206842, Asheville, North Carolina, 28801, United States|Atrium Health Carolinas Medical Center /ID# 206085, Charlotte, North Carolina, 28203, United States|Charlotte Gastroenterology and Hepatology, PLLC /ID# 206138, Charlotte, North Carolina, 28207, United States|Wake Forest Baptist Medical Center /ID# 206067, Winston-Salem, North Carolina, 27157-0001, United States|Duplicate_Plains Clinical Research Center, LLC /ID# 205111, Fargo, North Dakota, 58104, United States|University of Cincinnati /ID# 205633, Cincinnati, Ohio, 45267-0585, United States|The Ohio State University /ID# 205637, Columbus, Ohio, 43210, United States|Optimed Research, Ltd. /ID# 205638, Columbus, Ohio, 43235, United States|Hometown Urgent Care and Resea /ID# 205630, Dayton, Ohio, 45424, United States|Dayton Gastroenterology, Inc. /ID# 205639, Englewood, Ohio, 45415, United States|Great Lakes Gastroenterology Research LLC /ID# 205631, Mentor, Ohio, 44060-6211, United States|Hightower Clinical /ID# 216336, Oklahoma City, Oklahoma, 73102, United States|Digestive Disease Specialists /ID# 206076, Oklahoma City, Oklahoma, 73112, United States|Options Health Research, LLC /ID# 206707, Tulsa, Oklahoma, 74104, United States|Healthcare Research Consultant /ID# 206706, Tulsa, Oklahoma, 74135, United States|Guthrie Medical Group, PC /ID# 206078, Sayre, Pennsylvania, 18840, United States|Pharmacorp Clinical Trials /ID# 206074, Charleston, South Carolina, 29412, United States|Gastroenterology Associates, P.A. of Greenville /ID# 206098, Greenville, South Carolina, 29615-3593, United States|Gastro One /ID# 206178, Germantown, Tennessee, 38138, United States|East Tennessee Research Institute /ID# 206169, Johnson City, Tennessee, 37604, United States|Quality Medical Research /ID# 206088, Nashville, Tennessee, 37211, United States|Vanderbilt University Medical Center /ID# 210405, Nashville, Tennessee, 37232-0011, United States|TX Clinical Research Institute /ID# 206718, Arlington, Texas, 76012, United States|Inquest Clinical Research /ID# 206132, Baytown, Texas, 77521, United States|Texas Digestive Disease Consultants /ID# 209805, Cedar Park, Texas, 78613-5028, United States|Texas Digestive Disease Consultants /ID# 209948, Cedar Park, Texas, 78613-5028, United States|Baylor Scott & White Center for Inflammatory Bowel Diseases /ID# 207484, Dallas, Texas, 75246, United States|DHAT Research Institute /ID# 206716, Garland, Texas, 75044-2208, United States|Vilo Research Group Inc /ID# 212625, Houston, Texas, 77017-2337, United States|Baylor College of Medicine - Baylor Medical Center /ID# 206717, Houston, Texas, 77030-3411, United States|Centex Studies, Inc. - Houston /ID# 206168, Houston, Texas, 77058, United States|GI Specialists of Houston /ID# 206090, Houston, Texas, 77070-4347, United States|Caprock Gastro Research /ID# 215115, Lubbock, Texas, 79424-3017, United States|Clinical Associates in Research Therapeutics of America, LLC /ID# 206710, San Antonio, Texas, 78212, United States|Southern Star Research Institute, LLC /ID# 205379, San Antonio, Texas, 78229-5390, United States|Baylor Scott & White Center for Diagnostic Medicine /ID# 206096, Temple, Texas, 76508, United States|Duplicate_Tyler Research Institue /ID# 206075, Tyler, Texas, 75701, United States|Gastro Health & Nutrition - Victoria /ID# 205378, Victoria, Texas, 77904, United States|Advanced Research Institute /ID# 206133, Ogden, Utah, 84403, United States|Ctr for Gastrointestinal Healt /ID# 208475, Franklin, Virginia, 23851, United States|Washington Gastroenterology Associates /ID# 206177, Bellevue, Washington, 98004, United States|Virginia Mason - Seattle Orthapedics /ID# 206070, Seattle, Washington, 98101, United States|The Vancouver Clinic, INC. PS /ID# 204973, Vancouver, Washington, 98664, United States|Wisconsin Center for Advanced Research, a division of GI Associates, LLC /ID# 206917, Milwaukee, Wisconsin, 53215, United States|Froedtert Memorial Lutheran Hospital /ID# 206945, Milwaukee, Wisconsin, 53226-3522, United States|Cardio Alem /ID# 211282, San Isidro, Buenos Aires, 1642, Argentina|Mautalen Salud e Investigacion /ID# 206033, Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires, 1128, Argentina|Hospital Britanico de Buenos Aires /ID# 209497, Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires, 1280, Argentina|Gedyt /ID# 210017, Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires, 1426, Argentina|Hospital Privado Univesitario /ID# 206030, Cordoba, 5016, Argentina|Macquarie University Hospital /ID# 211955, Macquarie University, New South Wales, 2109, Australia|Duplicate_Mater Misericordiae /ID# 212687, South Brisbane, Queensland, 4101, Australia|Griffith University /ID# 211956, Southport, Queensland, 4222, Australia|St Vincent's Hospital Melbourne /ID# 205758, Fitzroy, Victoria, 3065, Australia|Monash Medical Centre /ID# 206486, Melbourne, Victoria, 3168, Australia|Fiona Stanley Hospital /ID# 211642, Murdoch, Western Australia, 6150, Australia|Klinik Landstrasse /ID# 205764, Vienna, Wien, 1030, Austria|Medical University of Vienna /ID# 205763, Vienna, Wien, 1090, Austria|LKH Salzburg and Paracelsus /ID# 208788, Salzburg, 5020, Austria|Universitair Ziekenhuis Leuven /ID# 205988, Leuven, Vlaams-Brabant, 3000, Belgium|AZ Maria Middelares /ID# 210928, Gent, 9000, Belgium|University Clinical Centre of the Republic of Srpska /ID# 208053, Banja Luka, Republika Srpska, 78000, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska /ID# 208055, Banja Luka, Republika Srpska, 78000, Bosnia and Herzegovina|University Clinical Center Tuzla /ID# 208057, Tuzla, Tuzlanski, 75000, Bosnia and Herzegovina|University Clinical Hospital Mostar /ID# 208054, Mostar, 88000, Bosnia and Herzegovina|Clinical Center University of Sarajevo /ID# 208058, Sarajevo, 71000, Bosnia and Herzegovina|Hospital Nossa Senhora das Graças /ID# 206981, Curitiba, Parana, 80810-040, Brazil|Hospital de Clinicas de Porto Alegre /ID# 206985, Porto Alegre, Rio Grande Do Sul, 90035-903, Brazil|Upeclin Fmb - Unesp /Id# 206986, Botucatu, Sao Paulo, 18618-686, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto - USP /ID# 206504, Ribeirão Preto, Sao Paulo, 14051-140, Brazil|Faculdade de Medicina do ABC /ID# 206984, Santo André, Sao Paulo, 09060-870, Brazil|Kaiser Clinica e Hospital Dia /ID# 206982, Sao Jose Do Rio Preto, Sao Paulo, 15015-110, Brazil|University of Calgary - Cumming School of Medicine - Adult Cystic Fibrosis Clini /ID# 205755, Calgary, Alberta, T2N 4Z6, Canada|Allen Whey Khye Lim Professional Corporation /ID# 211167, Edmonton, Alberta, T5R 1W2, Canada|Covenant Health /ID# 205500, Edmonton, Alberta, T6K 4B2, Canada|Percuro Clinical Research, Ltd /ID# 205501, Victoria, British Columbia, V8V 3M9, Canada|Duplicate_Toronto Digestive Disease Asso /ID# 205498, Vaughan, Ontario, L4L 4Y7, Canada|Crchum /Id# 207387, Montreal, Quebec, H2X 0A9, Canada|CIUSSS de l'Estrie - CHUS /ID# 205499, Sherbrooke, Quebec, J1G 2E8, Canada|Research Group /ID# 208037, Santiago, Region Metropolitana De Santiago, 2540364, Chile|M y F Estudios Clínicos Ltda. /ID# 208035, Santiago, Region Metropolitana De Santiago, 7750495, Chile|Hospital Guillermo Grant Benavente de Concepción /ID# 212426, Concepción, 4070038, Chile|CTR Estudios Clinicos /ID# 208036, Providencia, 7500571, Chile|Hospital Clinico Universidad De Los Andes /ID# 207426, Santiago, 7501504, Chile|Sun Yat-sen Memorial Hospital of Sun Yat-sen University /ID# 205267, Guangzhou, Guangdong, 510120, China|The Sixth Affiliated Hosp Sun /ID# 205268, Guangzhou, Guangdong, 510655, China|Affiliated Taihe Hospital of Hubei University of Medicine /ID# 216406, Shiyan, Hubei, 442700, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 205266, Wuhan, Hubei, 430022, China|The First Affiliated Hospital of Nanchang University /ID# 212186, Nanchang, Jiangxi, 330006, China|The First Hospital of Jilin University /ID# 210088, Changchun, Jilin, 130021, China|Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 205333, Shanghai, Shanghai, 200025, China|The second Affiliated hospital of Zhejiang University school of Medicine /ID# 205271, Hangzhou, Zhejiang, 310009, China|West China Hospital, Sichuan University /ID# 205332, Chengdu, 610041, China|Duplicate_Tianjin Med Univ General Hosp /ID# 205246, Tianjin, 300052, China|Tongji Hospital Tongji Medical College Huazhong University of Science and Techno /ID# 205265, Wuhan, 430030, China|Instituto Medico de Alta Tecnologia Oncomédica S.A /ID# 208887, Monteria, Cordoba, 230002, Colombia|Corporacion Hospitalaria Juan Cuidad Sede Denominada Hospital Universitario Mayo /ID# 208886, Bogota DC, Cundinamarca, 111221, Colombia|Hospital Universitario San Vic /ID# 208888, Medellin, 50010, Colombia|Klinicka bolnica Dubrava Zagreb /ID# 208460, Zagreb, Grad Zagreb, 10000, Croatia|Poliklinika Solmed /ID# 211568, Zagreb, Grad Zagreb, 10000, Croatia|Klinicki bolnicki centar Rijeka /ID# 208650, Rijeka, Primorsko-goranska Zupanija, 51000, Croatia|Klinicki bolnicki centar Split /ID# 217027, Split, 21000, Croatia|Hepato-Gastroenterologie HK, s.r.o. /ID# 205672, Hradec Kralove, 500 12, Czechia|CTCenter MaVe s.r.o. /ID# 205671, Olomouc, 779 00, Czechia|Artroscan s.r.o. /ID# 205668, Ostrava, 722 00, Czechia|Nemocnice Pardubickeho kraje, a.s. /ID# 213540, Pardubice, 530 03, Czechia|Nemocnice Milosrdnych sester sv. Karla Boromejskeho v Praze /ID# 216223, Praha, 118 33, Czechia|Axon Clinical, s.r.o. /ID# 205670, Praha, 140 00, Czechia|ISCARE a.s. /ID# 209240, Praha, 190 00, Czechia|East Tallinn Central Hospital /ID# 207564, Tallinn, Harjumaa, 10138, Estonia|West Tallinn Central Hospital /ID# 207356, Tallinn, 10617, Estonia|North Estonia Medical Centre /ID# 207357, Tallinn, 13419, Estonia|Tartu University Hospital /ID# 212282, Tartu, 51014, Estonia|Tampere University Hospital /ID# 206161, Tampere, Pirkanmaa, 33520, Finland|Keski-Suomen Sairaala Nova /ID# 206159, Jyvaskyla, 40620, Finland|Laakarikeskus Ikioma /ID# 205814, Mikkeli, 50100, Finland|Tyks /Id# 205813, Turku, 20521, Finland|Chu de Nice-Hopital L'Archet Ii /Id# 209118, Nice CEDEX 3, Alpes-Maritimes, 06202, France|Centre Hospitalier Lyon Sud /ID# 209121, Pierre Benite CEDEX, Rhone, 69495, France|Universitatsklinikum Mannheim /ID# 206811, Mannheim, Baden-Wuerttemberg, 68167, Germany|Duplicate_Universitaetsklinikum Tuebingen /ID# 206737, Tübingen, Baden-Wuerttemberg, 72076, Germany|Gastroenterologische Gemeinschaftspraxis Herne /ID# 214576, Herne, Nordrhein-Westfalen, 44623, Germany|Zentrum für Gastroenterologie Saar MVZ GmbH /ID# 215813, Saarbrücken, Saarland, 66111, Germany|Duplicate_Praxis am Bayrischen Platz /ID# 206733, Berlin, 10825, Germany|Agaplesion Markus Krankenhaus /ID# 206731, Frankfurt am Main, 60431, Germany|Duplicate_Univ Hosp Schleswig-Holstein /ID# 206791, Kiel, 24105, Germany|Medizinisches Versorgungszentrum Portal 10 /ID# 207137, Muenster, 48155, Germany|General Hospital of Athens Laiko /ID# 208671, Athens, Attiki, 11527, Greece|University General Hospital of Heraklion PA.G.N.I /ID# 207061, Heraklion, Kriti, 711 10, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 206332, Athens, 10676, Greece|Duplicate_General Hospital of Thessaloniki Hippokrateio /ID# 208822, Thessaloniki, 54642, Greece|Bekes Megyei Kozponti Korhaz /ID# 205885, Bekescsaba, 5600, Hungary|Semmelweis Egyetem /ID# 205883, Budapest, 1085, Hungary|Soproni Erzsebet Oktato Korhaz es Rehabilitacios Intezet /ID# 207992, Sopron, 9400, Hungary|Mentahaz Maganorvosi Kozpont /ID# 205882, Szekesfehervar, 8000, Hungary|Beaumont Hospital /ID# 206509, Dublin, D09 XR63, Ireland|University Hospital Galway /ID# 218035, Galway, H91 YR71, Ireland|Rambam Health Care Campus /ID# 206362, Haifa, 3109601, Israel|Shaare Zedek Medical Center /ID# 206365, Jerusalem, 91031, Israel|A.O.U. Policlinico S.Orsola-Malpighi /ID# 206351, Bologna, Emilia-Romagna, 40138, Italy|ASST Rhodense/Presidio Ospedaliero di Rho /ID# 216611, Rho, Milano, 20017, Italy|Istituto Clinico Humanitas /ID# 206346, Rozzano, Milano, 20089, Italy|Presidio Columbus-Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Un /ID# 206347, Rome, Roma, 00168, Italy|IRCCS Ospedale Sacro Cuore Don Calabria /ID# 206354, Negrar, Verona, 37024, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 206349, Milan, 20122, Italy|A.O. Ospedali Riuniti Villa Sofia - Cervello /ID# 206350, Palermo, 90146, Italy|Nagoya City University Hospital /ID# 206058, Nagoya shi, Aichi, 467-8602, Japan|Nagoya University Hospital /ID# 206355, Nagoyashi, Aichi, 4668560, Japan|Toyohashi Municipal Hospital /ID# 207625, Toyohashi-shi, Aichi, 441-8570, Japan|Ieda Hospital /ID# 207479, Toyota-shi, Aichi, 470-1219, Japan|Hirosaki National Hospital /ID# 206387, Hirosaki-shi, Aomori, 036-8545, Japan|Tokatsu Tsujinaka Hospital /ID# 214963, Abiko-shi, Chiba, 270-1168, Japan|Tsujinaka Hospital Kashiwanoha /ID# 209573, Kashiwa-shi, Chiba, 277-0871, Japan|Toho University Medical Center Sakura Hospital /ID# 207705, Sakura-shi, Chiba, 285-8741, Japan|Juntendo University Urayasu Hospital /ID# 208784, Urayasu-shi, Chiba, 279-0021, Japan|Fukui Prefectural Hospital /ID# 210449, Fukui-shi, Fukui, 910-8526, Japan|Fukuoka University Chikushi Hospital /ID# 214405, Chikushino-shi, Fukuoka, 818-8502, Japan|Saiseikai Fukuoka Genaral Hospital /ID# 209482, Fukuoka-shi, Fukuoka, 810-0001, Japan|Kurume University Hospital /ID# 206385, Kurume-shi, Fukuoka, 830-0011, Japan|Ogaki Municipal Hospital /ID# 208227, Ogaki-shi, Gifu, 503-8502, Japan|NHO Fukuyama Medical Center /ID# 206295, Fukuyama-shi, Hiroshima, 720-8520, Japan|Hiroshima University Hospital /ID# 206464, Hiroshima-shi, Hiroshima, 734-8551, Japan|Asahikawa Medical University Hospital /ID# 206404, Midorigaokahiga-shi, Hokkaido, 078-8510, Japan|Obihiro kosei Hospital /ID# 210424, Obihiro-shi, Hokkaido, 080-0024, Japan|Sapporo Tokushukai Hospital /ID# 209448, Sapporo-shi, Hokkaido, 004-0041, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 206059, Sapporo-shi, Hokkaido, 060-0033, Japan|Sapporo Medical University Hospital /ID# 206314, Sapporo-shi, Hokkaido, 060-8543, Japan|Sapporo Higashi Tokushukai Hospital /ID# 208494, Sapporo-shi, Hokkaido, 065-0033, Japan|Aoyama Clinic /ID# 206452, Kobe-shi, Hyogo, 650-0015, Japan|Hyogo College of Medicine Hospital /ID# 206455, Nishinomiya-shi, Hyogo, 663-8501, Japan|Kanazawa University Hospital /ID# 206316, Kanazawa-shi, Ishikawa, 920-8641, Japan|Iwate Medical University Uchimaru Medical Center /ID# 207051, Morioka-shi, Iwate, 020-8505, Japan|Idzuro Imamura Hospital /ID# 207639, Kagoshima-shi, Kagoshima, 892-0824, Japan|Sameshima Hospital /ID# 207935, Kagoshima-shi, Kagoshima, 892-0846, Japan|St. Marianna University School of Medicine Hospital /ID# 209451, Kawasaki-shi, Kanagawa, 216-8511, Japan|Showa University Fujigaoka Hospital /ID# 208224, Yokohama-shi, Kanagawa, 227-8501, Japan|Kyoto University Hospital /ID# 211809, Kyoto-shi, Kyoto, 606-8507, Japan|Mie University Hospital /ID# 206803, Tsu-shi, Mie, 514-8507, Japan|Yokkaichi Hazu Medical Center /ID# 214348, Yokkaichi-shi, Mie, 510-0016, Japan|National Hospital Organization Sendai Medical Center /ID# 209528, Sendai-shi, Miyagi, 983-8520, Japan|NHO Nagasaki Medical Center /ID# 210822, Omura-shi, Nagasaki, 856-8562, Japan|Kenseikai Dongo Hospital /ID# 208101, Yamatotakada-shi, Nara, 635-0022, Japan|Saiseikai Niigata Hospital /ID# 209921, Niigata-shi, Niigata, 950-1104, Japan|Niigata University Medical & Dental Hospital /ID# 218049, Niigata-shi, Niigata, 951-8520, Japan|Ishida Clinic of IBD and Gastroenterology /ID# 210119, Oita-shi, Oita, 870-0823, Japan|Chikuba Hospital for Proctological and Gastrointestinal Diseases /ID# 206646, Kurashiki-shi, Okayama, 710-0142, Japan|Okayama University Hospital /ID# 217925, Okayama-shi, Okayama, 700-8558, Japan|Kinshukai Infusion Clinic /ID# 207865, Osaka-shi, Osaka, 530-0011, Japan|Kitano Hospital /ID# 210397, Osaka-shi, Osaka, 530-8480, Japan|Japanese Red Cross Osaka Hospital /ID# 209478, Osaka-shi, Osaka, 543-8555, Japan|Osaka City University Hospital /ID# 206457, Osaka-shi, Osaka, 545-8586, Japan|Toyonaka Municipal Hospital /ID# 217082, Toyonaka-shi, Osaka, 560-0055, Japan|Saga University Hospital /ID# 209270, Saga-shi, Saga, 849-8501, Japan|Saitama Medical Center /ID# 206393, Kawagoe-shi, Saitama, 350-8550, Japan|Tokitokai Tokito clinic /ID# 206313, Saitama-shi, Saitama, 336-0963, Japan|National Hospital Organization Higashi-Ohmi General Medical Center /ID# 210710, Higashi-ohmi-shi, Shiga, 527-8505, Japan|Shimane University School of Medicine /ID# 208905, Izumo-shi, Shimane, 693-0021, Japan|Hamamatsu University Hospital /ID# 206459, Hamamatsu-shi, Shizuoka, 431-3192, Japan|NHO Shizuoka Medical Center /ID# 208785, Sunto-gun, Shizuoka, 411-8611, Japan|Tokyo Medical And Dental University, Medical Hospital /ID# 206453, Bunkyo-ku, Tokyo, 113-8519, Japan|St.Luke's International Hospital /ID# 208076, Chuo-ku, Tokyo, 104-8560, Japan|Tokai University Hachioji Hospital /ID# 208903, Hachioji-shi, Tokyo, 192-0032, Japan|Teikyo University Hospital /ID# 209866, Itabashi-ku, Tokyo, 173-8606, Japan|Center Hospital of the National Center for Global Health and Medicine /ID# 209532, Shinjuku-ku, Tokyo, 162-8655, Japan|Tokyo Women's Medical University Hospital /ID# 206460, Shinjuku-ku, Tokyo, 162-8666, Japan|Yamagata University Hospital /ID# 206465, Yamagata-shi, Yamagata, 990-9585, Japan|Tokuyama Central Hospital /ID# 216994, Shunan-shi, Yamaguchi, 745-8522, Japan|Shoyukai Fujita Gastroenterological Hospital /ID# 216493, Takatsuki-shi, 569-0086, Japan|Kangbuk Samsung Hospital /ID# 206960, Seoul, Seoul Teugbyeolsi, 03181, Korea, Republic of|Dong-A University Hospital /ID# 206955, Busan, 49201, Korea, Republic of|Pusan National University Hospital /ID# 206956, Busan, 49241, Korea, Republic of|Yeungnam University Medical Center /ID# 206959, Daegu, 42415, Korea, Republic of|Duplicate_CHA Bundang Medical Center /ID# 207432, Seongnam-si, Gyeonggi-do, 13496, Korea, Republic of|Yonsei University Health System, Severance hospital /ID# 206958, Seoul, 03722, Korea, Republic of|Riga East Clinical Univ Hosp /ID# 206828, Riga, 1038, Latvia|P. Stradins Clinical Univ Hosp /ID# 206827, Riga, LV-1002, Latvia|Hospital of Lithuanian University of Health Sciences Kaunas Clinics /ID# 209052, Kaunas, 50161, Lithuania|Klaipeda Seamens Hospital /ID# 208791, Klaipeda, 92288, Lithuania|Klaipeda University Hospital /ID# 208790, Klaipeda, 92288, Lithuania|Vilnius University Hospital /ID# 209051, Vilnius, LT-08661, Lithuania|Universiti Kebangsaan Malaysia (UKM) Medical Centre /ID# 207662, Kuala Lumpur, Selangor, 56000, Malaysia|Duplicate_Uni Malaya MC /ID# 208936, Kuala Lumpur, 59100, Malaysia|Morales Vargas Centro de Investigacion S.C. /ID# 211326, Leon, Guanajuato, 37000, Mexico|Clinica de Investigacion en Reumatologia y Obesidad S.C. /ID# 208068, Guadalajara, Jalisco, 44650, Mexico|Centro Regiomontano de Estudios Clínicos ROMA S.C /ID# 208067, Monterrey, Nuevo Leon, 64610, Mexico|Erasmus Medisch Centrum /ID# 205280, Rotterdam, 3015 GD, Netherlands|Akershus Universitetssykehus_MAIN /ID# 205293, Lorenskog, Akershus, 1478, Norway|Universitetssykehuset Nord-Norge /ID# 205691, Tromsø, Troms, 9019, Norway|Gastromed /Id# 216108, Torun, Kujawsko-pomorskie, 87-100, Poland|Centrum Medyczne Reuma Park w Warszawie /ID# 212913, Warsaw, Mazowieckie, 02-691, Poland|Centrum Zdrowia MDM /ID# 205874, Warszawa, Mazowieckie, 00-635, Poland|NZOZ Vivamed /ID# 216697, Warszawa, Mazowieckie, 03-580, Poland|Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 215070, Warszawa, Mazowieckie, 04-730, Poland|Endoskopia Sp. z o.o. /ID# 212964, Sopot, Pomorskie, 81-756, Poland|Hospital da Senhora da Oliveira Guimaraes, EPE /ID# 205554, Guimaraes, Braga, 4835-044, Portugal|Centro Hospitalar de Entre Douro e Vouga /ID# 205563, Santa Maria Da Feira, Porto, 4520-211, Portugal|Unidade Local de Saúde do Alto Minho, EPE - Hospital Conde de Bertiandos /ID# 205556, Ponte de Lima, Viana Do Castelo, 4990-041, Portugal|Hospital Garcia de Orta, EPE /ID# 206143, Almada, 2805-267, Portugal|CCA Braga - Hospital de Braga /ID# 206144, Braga, 4710-243, Portugal|Centro Hospitalar Universitário de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 206117, Lisboa, 1649-035, Portugal|Hospital Santo Antonio dos Cap /ID# 206145, Lisbon, 1150-069, Portugal|Centro Hospitalar Universitario de Sao Joao, EPE /ID# 206142, Porto, 4200-319, Portugal|School of Medicine University of Puerto Rico-Medical Science Campus /ID# 209626, San Juan, 00935, Puerto Rico|Immanuel Kant Baltic Federal University /ID# 208264, Kaliningrad, Kaliningradskaya Oblast, 236016, Russian Federation|NW State Medical Univ na Mechn /ID# 208258, St. Petersburg, Leningradskaya Oblast, 191015, Russian Federation|Perm Clinical Center of the Federal Medical and Biological Agency /ID# 211653, Perm, Permskiy Kray, 614109, Russian Federation|Medical Company Hepatolog /ID# 208261, Samara, Samarskaya Oblast, 443063, Russian Federation|Professor Pasechnikov Gastroenterology and Pankreatology clinic /ID# 211652, Stavropol, Stavropol Skiy Kray, 355012, Russian Federation|Kazan State Medical University /ID# 208256, Kazan, Tatarstan, Respublika, 420012, Russian Federation|Olla-Med Clinic /ID# 215335, Moscow, 105554, Russian Federation|Republican hospital named after V.A. Baranov /ID# 206507, Petrozavodsk, 185019, Russian Federation|Euromedservice /ID# 208265, Pushkin, 196603, Russian Federation|LLC Novaya Clinica /ID# 208260, Pyatigorsk, 357532, Russian Federation|Clinical Hosp Center Zvezdara /ID# 205258, Belgrade, Beograd, 11000, Serbia|Military Medical Academy /ID# 205257, Belgrade, Beograd, 11000, Serbia|University Clinical Center Serbia /ID# 205256, Belgrade, Beograd, 11000, Serbia|Clin Hosp Ctr Bezanijska Kosa /ID# 206413, Belgrade, Beograd, 11080, Serbia|University Clinical Center of Nis /ID# 206411, NIS, Nisavski Okrug, 18000, Serbia|University Clinical Center Kragujevac /ID# 206410, Kragujevac, Sumadijski Okrug, 34000, Serbia|Clinical Center Vojvodina /ID# 205259, Novi Sad, Vojvodina, 21000, Serbia|General Hospital Leskovac /ID# 217881, Leskovac, 16000, Serbia|National University Hospital /ID# 209099, Singapore, 119074, Singapore|Gleneagles Medical Centre /ID# 206954, Singapore, 258499, Singapore|Tan Tock Seng Hospital /ID# 207663, Singapore, 308433, Singapore|Medak s.r.o. /ID# 205191, Bratislava, Bratislavsky Kraj, 851 01, Slovakia|Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica /ID# 205147, Banska Bystrica, 975 17, Slovakia|B+B MED, s.r.o. /ID# 205213, Kosice, 040 01, Slovakia|Fakultna nemocnica s poliklini /ID# 211372, Nove Zamky, 940 34, Slovakia|GASTRO I., s.r.o. /ID# 205148, Presov, 080 01, Slovakia|MD Search /ID# 208084, Boksburg North, Gauteng, 1460, South Africa|Clinresco Centers /ID# 208083, Johannesburg, Gauteng, 1619, South Africa|Lenasia Clinical Trial Centre /ID# 214359, Johannesburg, Gauteng, 1820, South Africa|Wits Clinical Research , Wits Health Consortium (PTY) Ltd /ID# 208082, Johannesburg, Gauteng, 2193, South Africa|Wits Clinical Research Site /ID# 208949, Johannesburg, Gauteng, 2193, South Africa|Mediclinic Milnerton /ID# 207979, CAPE TOWN Milnerton, Western Cape, 7441, South Africa|Kingsbury Hospital /ID# 205281, Cape Town, Western Cape, 7708, South Africa|Private Practice Dr MN Rajabally /ID# 205273, Cape Town, Western Cape, 7800, South Africa|Hospital Clínico Universitario de Santiago-CHUS /ID# 204411, Santiago de Compostela, A Coruna, 15706, Spain|Hospital Unversitario Marques de Valdecilla /ID# 216622, Santander, Cantabria, 39008, Spain|Hospital Universitario Dr. Negrin /ID# 206905, Las Palmas de Gran Canaria, Las Palmas, 35010, Spain|Hospital Universitario A Coruna - CHUAC /ID# 206907, A Coruna, 15006, Spain|Hospital Clinic de Barcelona /ID# 206906, Barcelona, 08036, Spain|Hospital Universitario Reina Sofia /ID# 204412, Cordoba, 14004, Spain|Hospital Universitario Ramon y Cajal /ID# 204410, Madrid, 28034, Spain|Hospital Universitario La Paz /ID# 214540, Madrid, 28046, Spain|Hospital Clinico Universitario de Salamanca /ID# 205013, Salamanca, 37007, Spain|Hospital Universitario y Politecnico La Fe /ID# 206904, Valencia, 46026, Spain|Kantonsspital St. Gallen /ID# 211310, St. Gallen, Sankt Gallen, 9007, Switzerland|Universitaetsspital Basel /ID# 211381, Basel, 4031, Switzerland|Inselspital, Universitaetsklinik /ID# 211312, Bern, 3010, Switzerland|Universitaetsspital Zuerich /ID# 211308, Zurich, 8091, Switzerland|China Medical University Hosp /ID# 207845, Taichung City, Taichung, 40447, Taiwan|National Taiwan University Hospital /ID# 207847, Taipei City, Taipei, 100, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 207848, Kaohsiung, 80708, Taiwan|Taipei Veterans General Hosp /ID# 207849, Taipei City, 11217, Taiwan|Erciyes University Medical Fac /ID# 207506, Melikgazi, Kayseri, 38030, Turkey|Gazi University Med. Faculty /ID# 208040, Ankara GAZI, 06500, Turkey|Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty /ID# 207507, Istanbul, 34098, Turkey|Umraniye Training and Res Hosp /ID# 208206, Istanbul, 34764, Turkey|Mersin University Medical /ID# 208039, Mersin, 33343, Turkey|Communal Non-Commercial Enterprize of Kharkiv Regional Council Regional Clinical /ID# 206939, Kharkiv, Kharkivska Oblast, 61204, Ukraine|Kyiv Regional Hospital /ID# 217373, Kyiv, Kyivska Oblast, 04073, Ukraine|PE PMC Acinus, Medical and Diagnostic Center /ID# 217218, Kropyvnytskyi, 25006, Ukraine|Medical centre of CONSILIUM MEDICAL LLC /ID# 217447, Kyiv, 04050, Ukraine|Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrogov /ID# 216300, Vinnytsia, 21018, Ukraine|Basingstoke & North Hampshire /ID# 207985, Basingstoke, RG24 9NA, United Kingdom|Queen Elizabeth University Hos /ID# 205154, Glasgow, G514TF, United Kingdom|Huddersfield Royal Infirmary /ID# 217660, Huddersfield, HD3 3EA, United Kingdom|St. George's Healthcare NHS /ID# 208375, London, SW17 0QT, United Kingdom|Barts and the London NHS Trust /ID# 205153, Whitechapel, E1 1 BB, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/26/NCT03653026/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/26/NCT03653026/SAP_001.pdf",NCT03653026,"Inclusion Criteria:~- Male or female participants ≥ 16 and ≤ 75 years of age at Baseline Note: Adolescent participants at the age of 16 or 17 years old will be eligible to participate if approved by the country or regulatory/health authorities.~Note: Adolescent participants at the age of 16 or 17 years old must weigh ≥ 40 kilograms and meet the definition of Tanner Stage 5 at the Screening Visit.~* Diagnosis of Ulcerative Colitis (UC) for 90 days or greater prior to Baseline, confirmed by colonoscopy during the Screening Period, with exclusion of current infection, colonic dysplasia and/or malignancy. Appropriate documentation of biopsy results consistent with the diagnosis of UC, in the assessment of the Investigator, must be available.~* Active UC with an Adapted Mayo score of 5 to 9 points and endoscopic subscore of 2 to 3.~* Demonstrated an inadequate response, loss of response, or intolerance to at lease one of the following treatments including, oral aminosalicylates, corticosteroids, immunosuppressants, and/or biologic therapies.~Note: Participants who have had inadequate response, loss of response to conventional therapy but have not failed biologic therapy (Non-bio-IR) and have received a prior biologic for up to 1 year may be enrolled, however they must have discontinued the biologic for reasons other than inadequate response or intolerance (e.g., change of insurance, well controlled disease), and must meet criteria for inadequate response, loss of response, or intolerance as defined above.~* Female Participants of childbearing potential must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline Visit.~* If female, participant must meet the contraception recommendation criteria.~Exclusion Criteria:~* Participant with current diagnosis of Crohn's disease (CD) or diagnosis of indeterminate colitis (IC).~* Current diagnosis of fulminant colitis and/or toxic megacolon.~* Participant with disease limited to the rectum (ulcerative proctitis) during the Screening endoscopy.~* Received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 30 days prior to Baseline.~* Participant who received azathioprine or 6-mercaptopurine (6-MP) within 10 days of Baseline.~* Received intravenous corticosteroids within 14 days prior to Screening or during the Screening Period.~* Participant with previous exposure to Janus Activated Kinase (JAK) inhibitor (e.g., tofacitinib, baricitinib, filgotinib, upadacitinib).~* Screening laboratory and other analyses show any prespecified abnormal hematologic results.",2018.0,3.0,0.99530655,8,522.0,1.0,COMPLETED,2.34,-0.044,0,0
8203,10415,NCT02065557,Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis,https://clinicaltrials.gov/study/NCT02065557,,COMPLETED,"The purpose of the study is to demonstrate the efficacy and safety, and to assess the pharmacokinetics of adalimumab administered subcutaneously (SC) in pediatric subjects with moderate to severe ulcerative colitis (UC).",YES,Ulcerative Colitis,BIOLOGICAL: Adalimumab|BIOLOGICAL: Placebo,"Co-Primary Endpoint 1: Percentage of Participants Who Achieved Clinical Remission as Measured by Partial Mayo Score (PMS) at Week 8 - Induction Period, The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 sub scores (stool frequency, rectal bleeding and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). A negative change in PMS indicates improvement. Clinical remission was defined as a PMS ≤ 2 and no individual subscore \> 1., Week 8|Co-Primary Endpoint 2: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 52 in Week 8 Responders Per PMS - Maintenance Period, The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those with a decrease in PMS ≥ 2 points and ≥ 30% from Baseline. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1., Week 52","Ranked Secondary Endpoint 1: Percentage of Participants With Clinical Response Per FMS at Week 52 in Week 8 Responders Per PMS - Maintenance Period, The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those with a decrease in PMS ≥ 2 points and ≥ 30% from Baseline. Clinical response per FMS is defined as a decrease in FMS ≥ 3 points and ≥ 30% from Baseline., Week 52|Ranked Secondary Endpoint 2: Percentage of Participants With Mucosal Healing at Week 52 in Week 8 Responders Per PMS - Maintenance Period, The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those participants with a decrease in PMS ≥ 2 points and ≥ 30% from Baseline. Mucosal healing per Mayo endoscopy subscore is defined as a subscore of ≤ 1., Week 52|Ranked Secondary Endpoint 3: Percentage of Participants With Clinical Remission Per FMS at Week 52 in Week 8 Remitters Per PMS - Maintenance Period, The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS remitters are defined as those participants with a PMS ≤ 2 and no individual subscore \> 1. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1., Week 52|Ranked Secondary Endpoint 4: Percentage of Participants With Corticosteroid-Free Clinical Remission Per FMS at Week 52 in Week 8 Responders Per PMS - Maintenance Period, The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those with a decrease in PMS ≥ 2 points and ≥ 30% from baseline. Among participants receiving systemic corticosteroids at Baseline, corticosteroid-free clinical remission per FMS at Week 52 is defined as having discontinued systemic corticosteroids prior to Week 52 and being in FMS clinical remission at Week 52 (defined as Mayo Score ≤ 2 and no individual subscore \> 1)., Week 52",,AbbVie,,ALL,CHILD,PHASE3,101.0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",M11-290|2013-003032-77,2014-10-13,2020-02-07,2020-02-07,2014-02-19,2020-10-05,2020-10-05,"Childrens Hospital LA /ID# 147452, Los Angeles, California, 90027, United States|Univ California, San Francisco /ID# 120901, San Francisco, California, 94143-2204, United States|Arnold Palmer Hosp Children /ID# 120898, Orlando, Florida, 32806, United States|Emory University Hospital /ID# 121858, Atlanta, Georgia, 30322, United States|Children's Ctr Digestive, US /ID# 121855, Atlanta, Georgia, 30342, United States|University of Chicago /ID# 120904, Chicago, Illinois, 60637-1443, United States|Loyola University Medical Ctr /ID# 120900, Maywood, Illinois, 60153, United States|Indiana University /ID# 120908, Indianapolis, Indiana, 46202, United States|Massachusetts General Hospital /ID# 124551, Boston, Massachusetts, 02114, United States|Boston Childrens Hospital /ID# 147714, Boston, Massachusetts, 02115, United States|Mayo Clinic - Rochester /ID# 121056, Rochester, Minnesota, 55905-0001, United States|Minnesota Gastroenterology P.A /ID# 120895, Saint Paul, Minnesota, 55114, United States|Goryeb Chidlren's Hospital /ID# 121860, Morristown, New Jersey, 07960, United States|North Shore University Hospital /ID# 120905, New Hyde Park, New York, 11040, United States|Univ Rochester Med Ctr /ID# 127776, Rochester, New York, 14642, United States|Multicare Institute for Research and Innovation /ID# 147716, Tacoma, Washington, 98405, United States|Womens and Childrens Hospital /ID# 127538, Adelaide, South Australia, 5006, Australia|Medizinische Universitat Wien /ID# 120802, Vienna, Wien, 1090, Austria|LKH Salzburg and Paracelsus /ID# 123457, Salzburg, 5020, Austria|UZ Brussel /ID# 120798, Jette, Bruxelles-Capitale, 1090, Belgium|Cliniques Universitaires Saint Luc /ID# 120797, Woluwe-Saint-Lambert, Bruxelles-Capitale, 1200, Belgium|Hosp Univ Enfants Reine Fabiol /ID# 120795, Brussels, 1020, Belgium|London Health Sciences Centre /ID# 127777, London, Ontario, N6A 5A5, Canada|Palacky University /ID# 131388, Olomouc, 779 00, Czechia|Univ Hosp, Plzen, CZ /ID# 120813, Plzen, 305 99, Czechia|Petz Aladar Megyei Oktato Korh /ID# 124323, Gyor, 9023, Hungary|Balassa Janos County Hospital /ID# 128474, Szekszard, 7100, Hungary|Soroka Medical Ctr /ID# 147338, Be'er Sheva, 84101, Israel|Assaf Harofeh Medical Center /ID# 147791, Be'er Ya'akov, 70300, Israel|Rambam Health Care Campus /ID# 120827, Haifa, 3109601, Israel|Shaare Zedek Medical Center /ID# 120830, Jerusalem, 91031, Israel|Schneider Childrens Med Ctr /ID# 120821, Petah Tikva, 4920235, Israel|Sheba Medical Center /ID# 124324, Ramat Gan, 5262100, Israel|Kaplan Medical Center /ID# 150245, Rehovot, 76100, Israel|Kurume University Hospital /ID# 125476, Kurume-shi, Fukuoka, 830-0011, Japan|Gunma University Hospital /ID# 126345, Maebashi-shi, Gunma, 371-8511, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 124482, Sapporo-shi, Hokkaido, 060-0033, Japan|The Hospital of Hyogo College of Medicine /ID# 131665, Nishinomiya-shi, Hyogo, 663-8501, Japan|Saiseikai Yokohamashi Tobu /ID# 124486, Yokohama-shi, Kanagawa, 230-0012, Japan|Yokohama City Univ Medical Ctr /ID# 147763, Yokohama, Kanagawa, 232-0024, Japan|Miyagi Children's Hospital /ID# 125475, Sendai-shi, Miyagi, 989-3126, Japan|Saitama Children's Medical Center /ID# 124485, Saitama-shi, Saitama, 330-8777, Japan|Juntendo University Hospital /ID# 124536, Bunkyo-ku, Tokyo, 113-8431, Japan|National Center for Child Health and Development /ID# 125203, Setagaya-ku, Tokyo, 157-8535, Japan|Osaka General Medical Center /ID# 124535, Osaka, 558-8558, Japan|Canterbury District Health Boa /ID# 120837, Christchurch, 8011, New Zealand|Polish Mothers Memorial Hosp /ID# 148497, Lodz, Lodzkie, 93-338, Poland|Uni Szpital Dzieciecy w Krakowie /ID# 120915, Cracow, Malopolskie, 30-663, Poland|Centrum Zdrowia MDM /ID# 120910, Warsaw, Mazowieckie, 00-635, Poland|Gabinet Lekarski Bartosz Korcz /ID# 120916, Rzeszow, 35-210, Poland|Samodzielny Publiczny Szpital /ID# 120839, Wroclaw, 50-369, Poland|Univerzitna nemocnica Martin /ID# 120844, Martin, Zilinsky Kraj, 036 01, Slovakia|FN s poliklinikou F.D. Rooseve /ID# 120847, Banska Bystrica, 974 09, Slovakia|Univerzitna Nemocnica Bratislava /ID# 120842, Bratislava, 821 01, Slovakia|Hospital Univ Vall d'Hebron /ID# 120856, Barcelona, 08035, Spain|Hospital Infantil Universitario Nino Jesus /ID# 121862, Madrid, 28009, Spain|The Royal London Hospital /ID# 120861, London, London, City Of, E1 1BB, United Kingdom|The Royal Free Hospital /ID# 123142, London, London, City Of, NW3 2QG, United Kingdom|Royal Hosp for Sick Children /ID# 120864, Glasgow, G3 8SJ, United Kingdom|Manchester Royal Infirmary, Ma /ID# 120862, Manchester, M13 9WL, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/57/NCT02065557/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/57/NCT02065557/SAP_001.pdf",NCT02065557,"Inclusion Criteria:~* Diagnosis of UC for at least 12 weeks prior to screening, confirmed by endoscopy with biopsy.~* Active ulcerative colitis with a Mayo Score of 6 - 12 points and endoscopy subscore of 2 - 3 despite concurrent treatment with oral corticosteroids or immunosuppressants or both.~Exclusion Criteria:~* Subject with Crohn's disease (CD) or indeterminate colitis (IC).~* Current diagnosis of fulminant colitis and/or toxic megacolon.~* Subjects with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy.~* Chronic recurring infections or active tuberculosis (TB).",2014.0,6.0,0.99528205,9,101.0,1.0,COMPLETED,2.2,0.0,1,0
57904,73624,NCT03269695,"Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.",https://clinicaltrials.gov/study/NCT03269695,,TERMINATED,The purpose of this study is to determine if PF-06687234 is effective and safe as add-on therapy to infliximab in subjects with active ulcerative colitis who are not in remission.,YES,Ulcerative Colitis,DRUG: PF-06687234|DRUG: Placebo,"Percentage of Participants in Modified Clinical Remission at Week 12 (Traditional Endoscopic Subscore <=1, Observed Cases), The Mayo score consists of 4 subscores (Endoscopic, stool frequency, rectal bleeding and Physician's global assessment \[PGA\]), each graded 0 to 3 with the higher score indicating more severe disease activity. Modified clinical remission is defined as a modified total Mayo Score (total Mayo score excluding the PGA subscore) \<=2, no individual subscore \>1, traditional endoscopic subscore \<=1 (where mild friability was scored as of 1; moderate or severe friability was scored as 2) and rectal bleeding subscore=0. Participants with missing values were handled by observed case approach (the missing data were used as is). The percentage of participants achieving modified clinical remission was calculated based on the number of participants with observed data., Week 12|Percentage of Participants in Modified Clinical Remission at Week 12 (Traditional Mayo Endoscopic Subscore <=1, Treatment Failure Approach), The Mayo score consists of 4 subscores (Endoscopic, stool frequency, rectal bleeding and Physician's global assessment \[PGA\]), each graded 0 to 3 with the higher score indicating more severe disease activity. Modified clinical remission is defined as a modified total Mayo Score (total Mayo score excluding the PGA subscore) \<=2, no individual subscore \>1, traditional endoscopic subscore \<=1 (where mild friability was scored as of 1; moderate or severe friability was scored as 2) and rectal bleeding subscore=0. Participants with missing values were handled by treatment failure approach (participants who had missing value for any reasons were considered as treatment failures)., Week 12|Percentage of Participants in Modified Clinical Remission at Week 12 (Modified Mayo Endoscopy Subscore = 0 or 1, Observed Cases), The Mayo score consists of 4 subscores (Endoscopic, stool frequency, rectal bleeding and Physician's global assessment), each graded 0 to 3 with the higher score indicating more severe disease activity. Modified clinical remission is defined as a modified total Mayo Score (total Mayo score excluding the PGA subscore) with endoscopic subscore = 0 or 1 (where any friability was scored as a mayo endoscopic subscore of 2), stool frequency subscore = 0 or 1, and rectal bleeding subscore = 0. Participants with missing values were handled by observed case approach (the missing data were used as is). The percentage of participants achieving modified clinical remission was calculated based on the number of participants with observed data., Week 12|Percentage of Participants in Modified Clinical Remission at Week 12 (Modified Mayo Endoscopy Subscore = 0 or 1, Treatment Failure Approach), The Mayo score consists of 4 subscores (Endoscopic, stool frequency, rectal bleeding and Physician's global assessment \[PGA\]), each graded 0 to 3 with the higher score indicating more severe disease activity. Modified clinical remission is defined as a modified total Mayo Score (total Mayo score excluding the PGA subscore) with endoscopic subscore = 0 or 1 (where any friability was scored as a mayo endoscopic subscore of 2), stool frequency subscore = 0 or 1, and rectal bleeding subscore = 0. Participants with missing values were handled by treatment failure approach (participants who had missing value for any reasons were considered as treatment failures)., Week 12|Number of Participants With Treatment-Emergent Adverse Events (AEs; All Causalities), Treatment-emergent AEs are those with initial onset or that worsen in severity after the first dose of the study medication. All AEs in the table below were treatment-emergent AEs. An serious adverse event (SAE) is any untoward medical occurrence at any dose that: results in death; is life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect; or that is considered to be an important medical event that may jeopardize the participant or may require intervention to prevent one of the other AE outcomes. Severe AEs were defined as AEs that interfered significantly with participant's usual function. Both SAEs and severe AEs were according to the investigator's assessment., Baseline (Day 1) through and including a minimum of 28 calendar days after the last administration of the investigational products (22 weeks in total)|Number of Participants With Treatment-Emergent AEs (Treatment Related), Treatment-emergent AEs are those with initial onset or that worsen in severity after the first dose of the study medication. All AEs in the table below were treatment-emergent AEs. An SAE is any untoward medical occurrence at any dose that: results in death; is life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect; or that is considered to be an important medical event that may jeopardize the participant or may require intervention to prevent one of the other AE outcomes. Severe AEs were defined as AEs that interfered significantly with participant's usual function. Both SAEs and severe AEs were according to the investigator's assessment. Treatment-related AEs were also determined by the investigator., Baseline (Day 1) through and including a minimum of 28 calendar days after the last administration of the investigational products (22 weeks in total)|Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality, The laboratory tests as defined in the protocol, including hematology, chemistry, urinalysis and other, were performed. Baseline was defined as the last measurement prior to first dosing (Day 1)., From baseline through Week 16|Number of Participants With Categorical Vital Signs, Single sitting blood pressure (BP), pulse rate, and temperature were measured. At Day 1 and Week 1, BP and pulse were collected approximately 30 minutes prior to dosing, approximately 30 minutes post dosing and approximately 1 hour post dosing. For participants with no safety issues (eg, severe injection site reactions, severe elevations BP and/or pulse), BP and pulse were collected approximately 30 minutes prior to dosing and approximately 30 minutes post dosing from Weeks 2-16. Vital signs were analyzed as per pre-specified categories., From baseline through Week 16|Number of Participants With Categorical Electrocardiogram (ECG) Data, Twelve (12) lead ECGs were collected. All scheduled ECGs were performed after the participants had rested quietly for at least 10 minutes in a supine position. When the timing of these measurements coincided with a blood collection, the ECG was obtained prior to the nominal time of the blood collection, blood pressure, and pulse rate. ECG data were analyzed as per pre-specified categories. PR=pulse rate; QTc=QT interval corrected for heart rate; QTcF=QTc corrected using Fridericia's formula., From baseline through Week 16","Percentage of Participants With Endoscopic Improvement at Week 12 ( Observed Cases), Endoscopic improvement is defined as a decrease of \>=1 point in a modified endoscopic subscore (any friability is scored as 2) or an absolute endoscopy score of \<=1 without friability. Participants with missing values were handled by observed case approach (the missing data were used as is). The percentage of participants achieving endoscopic improvement was calculated based on the number of participants with observed data., Week 12|Percentage of Participants With Endoscopic Improvement at Week 12 ( Treatment Failure Approach), Endoscopic improvement is defined as a decrease of \>=1 point in a modified endoscopic subscore (any friability is scored as 2) or an absolute endoscopy score of \<=1 without friability. Participants with missing values were handled by treatment failure approach (participants who had missing value for any reasons were considered as treatment failures)., Week 12|Percentage of Participants Achieving Geboes Index Remission at Week 12 (Observed Cases), Geboes index is a structured six-grade classification system ordered as follows: 0, structural changes (sub-grade: 0-0.3); 1, chronic inflammatory infiltrate (sub-grade: 1-1.3); 2, lamina propria neutrophils and eosinophils (sub-grade: 2A-2B.3); 3, neutrophils in epithelium (sub-grade: 3-3.3); 4, crypt destruction (sub-grade: 4-4.3); and 5, erosion and ulceration (sub-grade: 5-5.4). The final index ranges from 0 to 5.4, with low score associated with no inflammation or less inflammation and high score associated with severe inflammation or ulceration. Geboes index remission was defined as Geboes index \< 3 and Grade 3 \< 3.1 at week 12. Participants with missing values were handled by observed case approach (the missing data were used as is). The percentage of participants achieving Geboes index remission was calculated based on the number of participants with observed data., Week 12|Change From Baseline in Robart's Histology Index at Week 12 (Observed Cases), Robart's histology index is based on the Geboes scores, and the final score is obtained by the summation of four main items (chronic inflammatory infiltrate level, lamina propria neutrophils, neutrophils in the epithelium, and erosion or ulceration), which are classified from 0 (no inflammation) to 3 (severe inflammation or ulceration), yielding a final score that ranges between 0 (no inflammation) and 33 (severe inflammation or ulceration). Participants with missing values were handled by observed case approach (the missing data were used as is)., Week 12|Percentage of Participants With a Clinical Response at Week 12 (Observed Cases), The Mayo score consists of 4 subscores (Endoscopic, stool frequency, rectal bleeding and Physician's global assessment \[PGA\]), each graded 0 to 3 with the higher score indicating more severe disease activity. Clinical response is defined with a decrease from baseline of at least 3 points in total Mayo score with at least 30% change, accompanied by at least one-point decrease or absolute score of 0 or 1 in rectal bleeding subscore. Participants with missing values were handled by observed case approach (the missing data were used as is)., Week 12|Percentage of Participants With a Clinical Response at Week 12 (Treatment Failure Approach), The Mayo score consists of 4 subscores (Endoscopic, stool frequency, rectal bleeding and Physician's global assessment \[PGA\]), each graded 0 to 3 with the higher score indicating more severe disease activity. Clinical response is defined with a decrease from baseline of at least 3 points in total Mayo score with at least 30% change, accompanied by at least one-point decrease or absolute score of 0 or 1 in rectal bleeding subscore. Participants with missing values were handled by treatment failure approach (participants who had missing value for any reasons were considered as treatment failures)., Week 12|Percentage of Participants With Change From Baseline in Derived Partial Mayo Score of <=2 With no Individual Subscore >1 at Weeks 2, 4, 8 and 12 (Observed Cases), The Mayo score is determined by the summation of 4 subscores (Endoscopic, stool frequency, rectal bleeding and Physician's global assessment \[PGA\]), each graded 0 (normal) to 3 (worst). Derived partial mayo score is defined as total Mayo score excluding the endoscopic subscore (stool frequency, rectal bleeding and PGA only), ranging from 0 (normal) to 9 (the most severe). The percentages of participants with change from baseline in derived partial Mayo score of \<=2 with no individual subscore \>1 at Weeks 2, 4, 8 and 12 were calculated for this endpoint. Participants with missing values were handled by observed case approach (the missing data were used as is). Generalized Linear Mixed Model (GLMM) was used with fixed effects of treatment, visit and treatment by visit interaction., Baseline, Weeks 2, 4, 8 and 12|Serum Concentrations of PF-06687234 20 mg, Samples for serum PF-06687234 concentration were collected approximately 30 minutes prior to dosing. Concentration values below the lower limit of quantification were excluded when calculating the geometric mean (geometric coefficient of variation)., Prior to dosing on Day 1 and at Weeks 1, 3, 7, 11, 12 (168 hours post dose) and 16|Percentage of Participants With the Development of Human Anti-Fusion Antibodies (HAFAs) and Neutralizing Antibodies (NAbs) Against PF-06687234, Plasma samples were analyzed for anti PF-06687234, anti PF-06687234 IL-10 neutralizing antibody (AB) and anti PF-06687234 single chain variable fragment (scFv) neutralizing AB. Samples inadvertently analyzed were excluded., At screening, Day 1, Weeks 3, 7, 11, 12 and 16 (prior to dosing)",,Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE2,20.0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",B7581002|2017-002108-28|BUILD UC,2017-12-20,2021-01-07,2021-01-07,2017-09-01,2021-12-28,2021-12-28,"Dothan Surgery Center, Dothan, Alabama, 36301, United States|Gut PC, dba Digestive Health Specialists of the Southeast, Dothan, Alabama, 36305, United States|Emory Investigational Drug Services, Atlanta, Georgia, 30322, United States|Emory University Hospital, Atlanta, Georgia, 30322, United States|Emory University School of Medicine, Atlanta, Georgia, 30322, United States|The Emory Clinic, Atlanta, Georgia, 30322, United States|Chevy Chase Endoscopy Center, Chevy Chase, Maryland, 20815, United States|MGG Group Co., Inc., Chevy Chase Clinical Research, Chevy Chase, Maryland, 20815, United States|Clinical Research Institute of Michigan, LLC, Chesterfield, Michigan, 48047, United States|East Valley Endoscopy, Grand Rapids, Michigan, 49546, United States|Eastside Endoscopy Center, Macomb, Michigan, 48044, United States|Eastside Endoscopy Center, Saint Clair Shores, Michigan, 48041, United States|Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center, Wyoming, Michigan, 49519, United States|Allegiance Research Specialists, Wauwatosa, Wisconsin, 53226, United States|Concord Repatriation General Hospital, Concord, New South Wales, 2139, Australia|Eastern Health-Box Hill Hospital, Box Hill, Victoria, 3128, Australia|St. Vincent's Hospital, Melbourne, Fitzroy, Victoria, 3065, Australia|The Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, 6150, Australia|St John Of God Health Care Inc. Trading as St. John of God Subiaco Hospital, Subiaco, Western Australia, 6008, Australia|CHC Montlegia, Liege, 4000, Belgium|Universitaetsklinikum Schleswig-Holstein Campus Kiel, Kiel, 24105, Germany|The Chaim Sheba Medical Center, Ramat-Gan, 5265601, Israel|ASST Rhodense - Ospedale di Circolo di Rho, Rho, Milano, 20017, Italy|Azienda Ospedaliera di Padova, Padova, 35128, Italy|Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, 00168, Italy|The Catholic University of Korea, St. Vincent's Hospital, Gyeonggi-do, 16247, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, 03181, Korea, Republic of|King Abdulaziz University Hospital, Jeddah, 22252, Saudi Arabia|King Abdullah International Medical Research Center, Riyadh, 11426, Saudi Arabia|King Khalid University Hospital, Riyadh, 11472, Saudi Arabia|CHC ""Dr Dragisa Misovic-Dedinje"", Belgrade, 11000, Serbia|Clinical Hospital Center Zvezdara - Clinic for Gastroenterology and Hepatology, Belgrade, 11000, Serbia|Mersin Universitesi Tip Fakultesi Hastanesi, Mersin, 33110, Turkey","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/95/NCT03269695/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/95/NCT03269695/SAP_001.pdf",NCT03269695,"Inclusion Criteria:~* Male and/or female subjects 18 years to 75 years of age and weight \> 40 kg at the time of informed consent.~* A diagnosis of active UC (histologic) for 4 months.~* Subjects with active UC as defined by (via screening endoscopy) a total Mayo Score of 4 or more but 9 or less and an endoscopic subscore of 2.or more.~* UC extending at least 15 cm proximal to the anal verge at the time of the screening endoscopy.~* Must be on a stable dose 5-10 mg/kg of Remicade, Inflectra, or Remsima for a minimum of 14 weeks with no anticipation of need for change in infliximab treatment regimen throughout the study~* Male subjects able to father children and female subjects of childbearing potential and at risk for pregnancy must agree to use two methods of contraception (at least one of which is considered as highly effective) throughout the study and until the Week 16 visit~Exclusion Criteria:~* Subjects with a diagnosis or documented history of total colectomy and/or pouchitis, indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, and diverticular disease associated with colitis, or clinical findings suggestive of Crohn's disease.~* Subjects need for surgery or with major elective surgery scheduled during the study.~* Subjects with extensive colitis for at least 8 years who have not had a colonoscopy with surveillance biopsies within 2 years prior to baseline.~* Subjects with history of or at screening endoscopy, biopsy documented colonic dysplasia or neoplasia.~* Subjects who require infliximab dosing interval other than every 6 weeks or every 8 weeks.~* Subjects displaying clinical signs of fulminant colitis or toxic megacolon, with primary sclerosing cholangitis, known colonic stricture, history of colonic, small bowel obstruction or resection, with history of or current colonic or small bowel stoma.~* Cyclic neutropenia, thrombocytopenia, lymphopenia, leukopenia or history of chronic anemia.~* Presence of active enteric infection.~* Known history of human immunodeficiency virus (HIV) based on documented history with positive serological test, or positive HIV serologic test.~* Presence of transplanted organ.~* Anticipated need for any live vaccine.~* Class III or Class IV heart failure.~* Acute coronary syndrome and any history of cerebrovascular disease.~* Subjects with current, or a history of QT prolongation.~* Subjects receiving the following therapies within the designated time period:~  * \>9 mg/day of oral budesonide or \>20 mg/day of prednisone or equivalent within 2 weeks prior to baseline.~ * IV, IM or topical (rectal) treatment of 5-ASA or corticosteroid enemas within 2 weeks prior to baseline.~ * Anti integrin inhibitors within 14 weeks prior to baseline.~ * Any use of natalizumab.~ * Interferon therapy within 8 weeks prior to baseline.~ * Prior treatment with lymphocyte depleting therapies and alkylating agents.~ * Received selective B lymphocyte depleting agents within 1 year prior to baseline.~ * Receiving leukocyte apheresis, granulocyte apheresis, or plasma exchange within 6 months of baseline.~ * JAK inhibitors within 3 months prior to baseline.~ * Any investigational procedures(s) or product(s)30 days prior to baseline.~* History of sensitivity to heparin or heparin induced thrombocytopenia~* Known history of hypersensitivity, intolerance, or allergic reaction to PF-06687234 or any constituent of the IP.",2017.0,4.0,0.99525017,10,20.0,1.0,TERMINATED,1.79,0.322,1,0
